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ABSTRACT 
Respiratory tract infections (RTIs) are estimated to cause 703.000 deaths annually in children 
below five years. The majority of RTIs in children are caused by viruses, yet the number of 
antivirals approved for treatment of these infections is very limited. Moreover, it is sometimes 
complicated to distinguish between bacterial and viral RTIs, which results in overuse of 
antibiotics. The aim of this thesis is to improve the understanding of the causative role of 
respiratory viruses in children with severe RTI, with the long-term goal to improve diagnostics, 
facilitate the development of new antiviral drugs and reduce unnecessary antibiotic use. To 
achieve this, a number of specific objectives have been assessed. 
The spread of the Influenza A H1N1(pdm09) i.e. the swine flu pandemic was slower than 
expected when it reached Europe during Spring 2009. This was suggested to be due to negative 
viral interference by circulating rhinovirus (RV). In Paper I, children with influenza-like illness 
were assessed during the swine flu pandemic in 2009. Co-infections were specifically assessed in 
influenza-positive patients with regard to disease severity. No significant difference was found 
between patients with single versus viral co-infection. Co-infection with influenza and RV was 
not uncommon, which contradicted the proposed hypothesis of viral interference. Moreover, 
the study showed that several different viruses were present in the children with suspected 
influenza, underscoring the overlap of disease presentation of different respiratory viruses.  
PCR is a very sensitive method for detecting viruses, yet the significance of a finding in 
upper respiratory specimens has been questioned. In Paper II, we assessed the role of viruses in 
acute respiratory illness in a case-control study. Respiratory syncytial virus (RSV), human 
metapneumovirus (hMPV) and parainfluenza virus were highly associated with acute 
respiratory illness. In contrast, detection of other viruses was common in asymptomatic 
controls, showing the complexity in interpreting PCR-positivity for these viruses. 
Community-acquired pneumonia (CAP) is a disease that traditionally has been considered a 
predominantly bacterial disease. Nevertheless, successful immunization against the two major 
bacterial causes, Streptococcus pneumoniae and Haemophilus influenza, has contributed to a 
declining incidence of the disease and has likely also led to a relative increase of other etiologic 
agents. In Paper III, the role of viruses in CAP was assessed in another case-control study. 
Viruses were detected in the majority of cases and RSV, hMPV and influenza were highly 
associated with CAP. The study suggests that viruses have a major role in childhood CAP and 
indicates that viral CAP is an underdiagnosed disease.  
Viral RTIs affect also immunosuppressed children. Neutropenia is a common adverse effect 
in children receiving chemotherapeutic treatment for malignancies. The condition highly 
increases the risk for septicemia, and fever is sometimes the only symptom. However, in the 
majority of episodes of febrile neutropenia, no causative agent can be identified. In Paper IV, 
respiratory viruses were assessed in immunosuppressed children during episodes of febrile 
neutropenia. Interestingly, respiratory viruses were detected in almost half of the episodes, 
whereas laboratory confirmed septicemia was infrequent (9%). Moreover, the majority of 
children had cleared their virus at follow-up suggesting a causal relationship between the 
detected viruses and the episodes of febrile neutropenia. 
This thesis has contributed to an improved understanding of the role of viruses in severe 
RTIs in children stressing the urgent need for new diagnostic tests that better distinguish 
between viral and bacterial disease. It also forwards the need for improved treatment options 
and new vaccines against viral RTIs in children. 
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1 BACKGROUND 
1.1 RESPIRATORY TRACT INFECTIONS 
Respiratory tract infection (RTI) is, second to neonatal complications, the most common cause 
of death in children and is estimated to cause 703.000 deaths annually in children below five 
years (1). Mortality is skewed to low- and middle-income countries yet RTIs attribute to 
significant morbidity also in high-income countries (1). Several pathogens including viruses, 
bacteria, and fungi are capable of infecting the respiratory tract yet the focus of this thesis is on 
viral RTIs. Advances in diagnostic methods such as the development of molecular-based clinical 
tests have revolutionized viral diagnostics and recently several novel viruses have been 
discovered (2–5). There is a lack of understanding of the epidemiology, the clinical presentation 
and significance of different respiratory virus infections, particularly of those that were only 
recently discovered (2).  
 
 
1.1.1 Anatomy of the Respiratory Tract 
The respiratory tract is commonly divided into the upper and lower respiratory tract. Most of 
the respiratory tract is covered by ciliated pseudostratified columnar epithelial cells whereas the 
oral cavity, the tonsils and epiglottis have a stratified squamous non-keratinized epithelium, 
possibly to withstand the abrasion associated with ingestion of food (figure 1). Conformational 
differences in the glycans covering the epithelial cells partly explain the tissue tropism and 
species-specificity for different pathogens (6).  
 
 
Figure 1. Epithelium in the respiratory tract. Ciliated pseudostratified columnar or respiratory 
epithelium in the lower respiratory tract (a) and stratified squamous epithelium in the oral cavity (b). 
 
 
1.1.1.1 Upper Respiratory Tract 
The upper respiratory tract consists of the oral and nasal cavities, the sinuses, the pharynx 
(oropharynx, nasopharynx, and laryngopharynx) and the larynx (7). The ear cavities are 
sometimes included given their anatomical connection to the nasopharynx through the 
Eustachian tube. The lymphoid tissue of Waldeyer’s tonsillar ring (including the pharyngeal 
tonsil or “adenoid” in the nasopharynx, the lingual tonsil on the posterior tongue, two palatine 
tonsils in the oropharynx and two tubal tonsils at the opening of the Eustachian tube) and the 
epiglottis are other important structures in the upper respiratory tract. Bacterial colonization of 
A B
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the upper respiratory tract is common in children, for instance approximately 30% of Swedish 
children and 60-90% of children in low-income countries are carriers of Streptococcus 
pneumoniae (8,9). Other important colonizing bacteria in children are Haemophilus influenzae, 
Staphylococcus aureus, group A Streptococci and Moraxella catharralis (8). Significant 
differences in the microbiota are seen between breastfeeding children and children receiving 
formula (10).  
The existence of viral colonization is debated. Plenty of respiratory viruses are detected in 
the respiratory tract of asymptomatic children and longitudinal studies have reported 
persistence of certain viruses for several weeks (11–13). Nonetheless, as viruses are intracellular 
organisms and as such dependent on the cellular machinery to replicate and persist, some argue 
that asymptomatic detection should not be considered colonization but rather subclinical or 
latent infection (12). 
  
 
1.1.1.2 Lower Respiratory Tract 
The lower respiratory tract consists of the trachea, the bronchi, the bronchioli and the lungs 
(alveoli and lung parenchyma). The lower respiratory tract has historically been considered a 
sterile site but metagenomic studies of lower respiratory specimens have revealed a plethora of 
resident microorganisms, thus challenging this old dogma (14). A certain confirmation of sialic 
acid-linked glycans, the target molecule or receptor for influenza virus, is found in the alveolar 
cells. This conformation, alpha(2,3), contrasts to the alpha(2,6) confirmation that is widespread 
in the upper respiratory tract (6). The impact of this was evident during the swine flu pandemic 
in 2009 where a certain mutation of the influenza virus was overrepresented in patients with 
severe lower respiratory tract infections in Norway (15). It was later shown that this mutation 
increased the virus affinity for alpha(2,6), which could have contributed to the high 
pathogenicity (15).  
 
 
1.1.1.3 Respiratory Specimens 
A veriety of respiratory specimens are obtained for diagnostic purposes depending on the 
severity of the disease and focus of the infection (table 1). The nasopharyngeal aspirate is 
considered gold-standard for upper respiratory infections but is also commonly used in 
diagnostics of lower respiratory infections under the assumption that the infecting pathogen 
entered the lower respiratory tract through micro-aspiration. Pleural fluid sampling, blood 
culture, bronchoalveolar lavage, lung aspirates and lung biopsies/autopsies are considered the 
gold standard for lower respiratory infections, but these specimens are either not feasible to 
obtain or lack sensitivity in children (16).  
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Table 1. Specimens for Diagnosing Respiratory Infections in Children 
Specimen Application Comment 
Nasal swab Rapid tests (Respiratory 
syncytial virus, influenza) 
Minimal discomfort for the child. 
Commonly used for rapid testing of 
respiratory syncytial virus and influenza. 
Nasopharyngeal 
aspirate/swab 
Upper respiratory tract 
infections 
Lower respiratory tract 
infections 
Gold standard sampling for influenza, 
bronchiolitis, atypical pneumonia and 
whooping cough.  
Oropharyngeal/throat swab Tonsillitis  
Expectorated sputum Pneumonia Hard to obtain from young children. 
Contaminated by pathogens from the 
upper respiratory tract. 
Induced sputum Pneumonia Acquired through inhalation of saline. 
Sensitive and tolerable for the child. 
Contaminated by pathogens from the 
upper respiratory tract. 
Pleural fluid Empyema/parapneumonic 
effusion 
Diagnostic and therapeutic intervention 
in pneumonia with pleural effusion. 
Bronchoalveolar lavage Severe lower respiratory 
tract infections 
Invasive, mainly used in the intensive care 
unit setting. 
Lung aspirate (Severe pneumonia) Rarely used in the clinic due to the 
invasive nature. Advantage of direct 
sampling from the lungs. Used widely in 
etiological studies during the 60s - 80s. 
Performed routinely in some African 
countries with reportedly low 
complication rate (17).  
Lung biopsy Severe lower respiratory 
tract infections with 
treatment failure (18). 
Only recommended in case of treatment 
failure in patients with severe pneumonia. 
Can be performed open or by 
thoracoscopy. 
Autopsy Fatal respiratory infections Advantage of direct sampling from the 
infectious focus.  
Urine antigen tests (Pneumonia)  
Available for 
pneumococci, legionella. 
Not recommended for routine use in 
children due to high colonization rates of 
the nasopharynx, which yields false-
positive results (18). 
Blood culture Severe pneumonia Poor sensitivity in children.  
Fecal tests Research Several respiratory viruses are detectable 
in fecal samples (19,20). 
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1.1.2 The Immune System 
Immunity comes from the latin word immunis meaning “exemption from military service or 
tax payment”. In medicine, it refers to the long-lasting protection against infection, which is 
maintained by specific immune cells in the body as well as by physical barriers. The immune 
system is commonly divided into the innate and the adaptive immune system. 
 
 
1.1.2.1 The Innate Immune System 
The innate immune system is the first line of defense. It consists of physical barriers, as well as a 
variety of cells specialized at sensing evolutionarily preserved patterns commonly found on 
microbes. The response is fast and constantly prevents us from being infected by microbes in 
the environment. Tightly arranged epithelial cells secrete antimicrobial peptides preventing 
microbes from penetrating the skin and the respiratory tract (21). Neutrophil granulocytes are 
specialized at phagocytizing, i.e. ingesting bacteria and dead tissue. Eosinophil granulocytes 
defend against parasites whereas the role of basophil granulocytes is less well understood. Both 
eosinophils and basophils are involved in the pathology of asthma and allergies. Monocytes such 
as macrophages and dendritic cells are specialized at presenting fragments of ingested pathogens 
to cells from the adaptive immune system thus providing a crucial link between the two parts of 
the immune systems. They also produce pro-inflammatory cytokines (IL-1, IL-6, TNF-α, etc) 
and chemokines. Natural killer cells are important in the defense against viruses and cancer 
cells. The complement system consists of plasma proteins that act as opsonins, i.e. they attach to 
intruding microbes to facilitate ingestion by phagocytizing cells. They also induce inflammation 
and kill microbes by forming pores in their membranes. Acute-phase proteins are peptides that 
rapidly increase in concentration in the blood following an infection and can opsonize certain 
pathogens. Some of these proteins such as C-reactive protein (CRP) are measured in the blood 
as markers of inflammation. 
 
 
1.1.2.2 The Adaptive Immune System 
The adaptive immune system consists of lymphocytes, highly specialized immune cells that 
create a tailor-made response to the intruding pathogen, once an infection is established. The 
response increases over time and usually provide long-lasting immunity against the pathogen. 
B-lymphocytes derive from the bone marrow and circulate in the blood as well as in the lymph 
nodes and in the spleen. They are important in the fight against mainly extracellular pathogens 
and can evolve into plasma cells, that produces immunoglobulins (Ig) or antibodies, soluble 
plasma proteins specifically targeting intruding pathogens. Antibodies from the mother are 
transfused to the child at birth (mainly IgG) and through breastfeeding (IgA) providing an 
efficient immune system to the newborn. Indeed, breastfeeding children acquire fewer 
infections as compared to those receiving formula (22). Most B-lymphocytes are short-lived, 
however, some evolve into memory cells after an infection that help maintain a long-lasting 
immunity to the pathogen. T-lymphocytes are specialized in fighting pathogens hiding inside 
human cells such as viruses and intracellular bacteria. This is maintained by induced cell death 
of the infected cells as well as by the production of cytokines stimulating cells in the innate 
immune system. All immune cells are initially produced in the yolk sack and liver during the 
embryonic phase but the production is relocated to the bone marrow after birth. Several 
immunological blood tests are routinely performed in the clinic, yet studies of the blood do not 
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always reflect what is happening in the peripheral tissue where most immune cells reside and 
where most of the host-pathogen interaction take place (23).  
 
 
1.1.3 Upper Respiratory Tract Infections 
Lack of immunity and high exposure at daycare centers and schools make upper respiratory 
tract infections (URTI) common in children. A longitudinal community surveillance study in 
Utah reported that children <5 years experienced respiratory symptoms in 38% of all weeks 
during the twelve months study period (11). Most URTIs have viral etiology and are self-
limiting, yet some may progress to severe infections in need of treatment (24). 
 
 
 
 
Figure 2. Pediatric infections in the respiratory tract. 1. Sinusitis, 2. Otitis media, 3. Pharyngitis, 4. 
Tonsillitis, 5. Epiglottitis, 6. Laryngotracheitis, 7. Bronchitis, 8. Bronchiolitis, 9. Pneumonia, 10. 
Parapneumonic effusion/empyema (pleuritis). 
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1.1.3.1 Common Cold (Nasopharyngitis) 
The common cold is a heterogeneous group of mild URTIs of predominantly viral etiology (24). 
Symptoms include coryza, sore throat, and cough (25). The disease is estimated to cause 22 
million days of absence from school annually in US children (26). The infections are in general 
self-limiting within two weeks and prolonged symptoms ≥2 weeks are usually due to serial 
infections (27). No curative treatment is available, nevertheless, nasal cleaning and intranasal 
anticongestives have a role in the treatment of infants to facilitate feeding. A placebo-controlled 
randomized trial reported a role of honey in alleviating nocturnal coughing and sleep 
difficulties (28). There is poor evidence for cough medicines and mucolytics (24). 
 
 
1.1.3.2 Pharyngotonsillitis 
Streptococcus pyogenes, or Group A streptococci (GAS) accounts for approximately 37% of all 
pharyngotonsillitis episodes in children, however, less common in children below two years 
(29,30). Viral and bacterial aetiology cannot be accurately distinguished by clinical examination 
(31).  Testing for GAS in children should be performed according to the Centor criteria (32). A 
rare but fearsome immunological complication to GAS pharyngotonsillitis is rheumatic fever, 
where destruction of the heart valves can lead to permanent heart failure. Antibiotic treatment 
seems to reduce the risk of the complication but the number needed to treat for one to benefit is 
very high in high-income countries (33). 
Both chronic and acute pharyngotonsillitis is associated with a high grade of virus detection 
yet anaerobic bacteria such as Fusobacterium necrophorum are increasingly being recognized as 
underreported causes in children (34,35). Anaerobic infection should be a differential diagnosis 
in adolescents due to the risk of thrombophlebitis and septic embolization (Lemierre syndrome) 
(36). Mononucleosis or kissing disease is mainly caused by Epstein-Barr virus but is also 
associated with some other herpesvirus infections (37). The disease is characterized by tonsillar 
enlargement, moderate-to-high fever, petechiae of the palate, bilateral lymphadenopathy and 
splenomegaly (37). The disease has a long incubation period and is primarily seen in teenagers. 
Restriction of physical activity should be recommended for 3-4 weeks after the infection due to 
an increased risk of splenic rupture (37). 
 
 
1.1.3.3 Acute Otitis Media 
Acute otitis media is a usually self-limiting infection of the middle ear. Complication such as 
mastoiditis and labyrinthitis are very rare (38). The disease has traditionally been considered a 
bacterial infection but the role of respiratory viruses is increasingly being recognized (12). 
Current guidelines from the American Academy of Pediatrics recommend observation with 
close follow-up for non-severe (mild otalgia ≤48h, fever <39°C) unilateral otitis in children >6 
months whereas antibiotic treatment with amoxicillin is recommended in complicated cases 
(38). In Sweden, antibiotic treatment with phenoxymethylpenicillin is recommended to 
children <1 year, adolescents and in complicated cases whereas observation with follow-up is 
recommended children 1-12 years with uncomplicated disease (39). 
 
 
1.1.3.4 Viral Croup (Laryngotracheitis) 
Viral croup is a mild self-limiting infection in the larynx, sometimes involving areas of the lower 
respiratory tract. The disease mainly affects children between six months and three years of age 
(40). Classical symptoms are difficulties breathing, barky cough and stridor due to 
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inflammation of the mucous membrane of the larynx. Worsening is commonly seen during the 
night-time hours, which has been suggested to be due to low levels of anti-inflammatory 
endogenous serum cortisol (40). The duration of the disease is short, usually <48 hours and 
hospitalization is seldom needed. Parainfluenza virus is the most common cause of viral croup, 
but several respiratory viruses have been associated with the disease (40). Treatment with 
steroids is recommended in moderately severe cases whereas inhalation of epinephrine and 
oxygen treatment is indicated only in severe cases (40). 
 
 
1.1.3.5 Other Upper Respiratory Tract Infections 
Owing to successful immunization programs, the lethal upper respiratory tract infections 
epiglottitis (primarily caused by Haemophilus influenzae type B) and diphtheria i.e. “true croup” 
(caused by Corynebacterium diphteriae) are rarely seen in vaccinated children. A decline in the 
incidence of sinusitis has been seen following the pneumococcal conjugate vaccine (41).  
 
 
1.1.4 Lower Respiratory Tract Infections  
An estimated 703.000 deaths can be attributed to lower respiratory tract infections (LRTI) in 
children under five years annually (42).  
 
 
1.1.4.1 Asthma and Wheezing 
Asthma is a heterogenic chronic disease of the respiratory tract that is characterized by 
hyperreactivity of the immune system. The disease can be IgE-mediated (allergic asthma) or not 
(non-allergic asthma). Wheezing or sibilant rhonchi refers to a characteristic high-pitched 
whistling sound heard upon lung auscultation in children with asthma as well as in some viral 
infections. Although asthma is not an infectious disease, the acute disease is commonly 
triggered by viral infections and can mimic respiratory infections such as wheezy bronchitis. 
Moreover, treatment with the antibiotic azithromycin have shown to shorten the length of 
asthma-like episodes in children, which suggests a role of bacteria in the acute disease (43). 
However, it could also be the result of an anti-inflammatory effect of macrolides that has 
previously been observed (44). 
Exposure to a large diversity of bacteria during childhood has been shown to be protective 
against asthma, which is commonly referred to as the hygiene hypothesis (45). In contrast, 
respiratory virus infections early in life have been associated with later development of asthma 
(46). It is not fully understood whether virus-induced wheezing is causing asthma or merely a 
first symptom of an underlying susceptibility (47).  
 
 
1.1.4.2 Bronchiolitis 
Bronchiolitis is a viral infection of the small airways in the lower respiratory tract. Acute 
inflammation with increased mucus production results in symptoms of coryza, cough, and low-
grade fever frequently progressing into severe breathing difficulties (tachypnea, nasal flaring, 
use of accessory muscles). Diagnosis is based on a characteristic wheezing upon pulmonary 
auscultation and x-ray is not needed in uncomplicated cases (48). Bronchiolitis is usually 
restricted to children below one year of age whereas the diagnoses of wheezy bronchitis, reactive 
airway disease or non-allergic asthma are used for wheezing non-asthmatic episodes in older 
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children (49,50). The most common causative agents are respiratory syncytial virus, 
metapneumovirus and rhinovirus (48). Supportive care including nutrition and supplemental 
oxygen (in children with oxyhaemoglobin saturation ≤90%) are sometimes necessary. 
Inhalation therapy with hypertonic saline might alleviate symptoms whereas inhalation of 
epinephrine and salbutamol are no longer recommended due to lack of evidence (48,51). 
Neither do corticosteroids or chest physiotherapy have a role in the treatment (48,51).  
 
 
1.1.4.3 Pneumonia 
Pneumonia is an infection in the lung parenchyma characterized by high fever, tachypnea, 
indrawings, productive cough and lethargy. Complications include empyema or 
parapneumonic effusion. The disease is commonly dived into nosocomial i.e. hospital-acquired 
and community-acquired pneumonia (CAP). The incidence of childhood CAP is currently 
decreasing owing to a globally improved nutritional status as well as to vaccination against the 
two major causing pathogens. A simplistic algorithm for diagnosing pneumonia was released in 
1990 by the World Health Organization (WHO) that was later included in the International 
Management of Childhood Illnesses (IMCI) strategy (table 2). The IMCI algorithm is based on 
respiratory rate, chest-wall indrawings, and cough and has been criticized for low specificity as 
episodes of bronchiolitis, asthma and dehydration frequently are misclassified as CAP (52). A 
clinical diagnosis is sufficient for non-severe cases that are treated as outpatients whereas 
radiographic confirmation is recommended in hospitalized patients (18). 
 
 
 
 
 
 
Image: Indrawings - A Common Sign in Children with Pneumonia. Reprint from WHO Pocket book 
of hospital care for children, 2nd edition, 2013. 
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Table 2 – IMCI Clinical Definition of Childhood Pneumonia.  
Sign or symptom Classification Treatment 
Cough or difficulty in breathing with: 
§ Oxygen saturation <90% or 
central cyanosis 
§ Severe respiratory distress (e.g.     
grunting, very severe chest 
indrawing) 
§ Signs of pneumonia with a general 
danger sign (inability to breastfeed 
or drink, lethargy or reduced level 
of consciousness, convulsions) 
Severe 
pneumonia 
- Admit to hospital. 
- Give oxygen if saturation <90%. 
- Manage airway as appropriate. 
- Give recommended antibiotic. 
- Treat high fever if present. 
Fast breathing: 
- ≥50 breaths/min in a child aged 2-11 
months 
- ≥40 breaths/min in a child aged 1-5 
years 
Chest indrawing 
Pneumonia - Home care. 
- Give appropriate antibiotic. 
- Advise the mother when to return 
immediately if symptoms of severe 
pneumonia. 
- Follow up after 3 days. 
No signs of pneumonia or severe 
pneumonia 
No pneumonia: 
cough or cold 
- Home care 
- Sooth the throat and relieve cough 
with safe remedy. 
- Advise the mother when to return. 
- Follow up after 5 days if not 
improving. 
Source: WHO Pocket book of hospital care for children. Abbreviations: IMCI, Integrated Management 
and of Childhood Illness. 
 
 
It is hard to establish etiology in childhood CAP. Bacterial blood cultures have limited 
sensitivity, respiratory specimens from the lungs are hard to acquire and specimens from the 
upper respiratory tract are clouded with bacterial colonization (53). Moreover, urine antigen 
tests for bacteria are not recommended for diagnostic purposes in children due to low 
specificity (18). Accordingly, an etiologic agent is rarely identified in children with CAP and 
antibiotic treatment is mostly prescribed empirically (16). Estimates of etiology of childhood 
pneumonia are largely varying (figure 3). During the 70s and 80s, several etiologic studies with 
invasive lung aspiration sampling were performed in low-income countries by the Board on 
Science and Technology for International Development. These studies identified bacterial 
causes in the majority of cases, primarily S. pneumoniae and H. influenzae and also identified 
the clinical signs associated with CAP that were later implemented in the IMCI guidelines (54). 
Viral causes were insufficiently studied due to diagnostic limitations. Later etiologic studies, 
mostly performed on upper respiratory specimens, have indicated an important role of 
respiratory viruses (55). 
 
 
 
                
  18 
 
Figure 3. Estimates of Community-Acquired Pneumonia Etiology in Children.  
Estimates by (a) Scott et al and b) Jain et al (16,56).  
 
 
During the 1990s, vaccination against H. influenza type B vaccination was introduced, and since 
2000, pneumococcal conjugate vaccines targeting certain serotypes of S. pneumoniae have 
gradually been introduced globally (57). This has likely contributed to the overall decline in 
CAP incidence seen in both low- and high-income countries (41). It is also hypothesized that, 
by targeting the two major bacterial causes, the relative proportion of viral etiology will increase 
(53). For long there has been a belief that viral infections pave the way for secondary bacterial 
infections. Yet increasing evidence point toward a role of viruses as sole causative agents of CAP 
(55,56,58,59). A randomized placebo-controlled trial of non-severe CAP (clinical diagnosis) in 
Pakistan showed similar rates of treatment failure for placebo and amoxicillin suggesting that a 
large proportion of the study subjects had viral disease and hence did not benefit from 
antibiotic treatment (60). In contrast, S. pneumoniae was identified in 91% of lung aspirates of 
unvaccinated Gambian children with severe CAP, of which >75% were serotypes covered by 
current pneumococcal conjugate vaccines (61). 
It is complicated to distinguish between viral and bacterial CAP and although commonly 
used, CRP is of limited use as certain viruses are associated with high CRP-levels (18). 
Parapneumonic effusion i.e. empyema is indicative of bacterial etiology with S. pneumoniae 
being the most common causative agent in unvaccinated settings (62). However, it is likely that 
the relative proportion of other bacteria such as Staphylococcus aureus will increase as etiologic 
agents in empyema given that invasive serotypes of S. pneumoniae are targeted by vaccines. 
There are contrasting data on the role of atypical bacteria, such as Mycoplasma pneumoniae and 
Clamydophila pneumoniae, in childhood CAP, particularly in children ≤5 years (63,64). 
Current diagnostic tests for M. pneumoniae are inconclusive (65).  
Swedish treatment guidelines for childhood CAP are focused solely on coverage of S. 
pneumoniae and penicillin V is recommended as first-line drug (66). The Infectious Disease 
Society of America recommends amoxicillin as first-line treatment in outpatients, whereas 
ampicillin or penicillin G are recommended for most hospitalized patients (18). This slightly 
extends the antimicrobial spectrum by adding additional coverage of most H. influenzae. In 
contrast, routine coverage for M. pneumoniae and C. pneumoniae is not considered necessary 
and should be restricted to patients with high suspicion of atypical etiology (18). Oral 
amoxicillin has been reported to be equivalent to parenteral penicillin G (67). For some reason, 
there seems to be a widespread skepticism to the usage of penicillin G among pediatricians and 
broad-spectrum beta-lactam antibiotics such as cephalosporins are widely used in hospitalized 
children with CAP (68). Nevertheless, Williams et al reported no difference in outcome between 
treatment with penicillin/ampicillin and third generation cephalosporins in hospitalized 
children with CAP in a retrospective register-based study using propensity score-matching (68).  
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1.1.5 Infections in Immunosuppressed Children 
Immunosuppression refers to an impaired function of any part of the immune system owing to 
a secondary environmental factor, in contrast to congenital or primary immune deficiencies. 
Neutropenia, defined as a neutrophil blood count of <1×109/L, is a common condition in 
children receiving chemotherapy as treatment for malignancies (69). The lowest neutrophil 
blood count, i.e. nadir, usually occurs 7-10 days after the treatment (70). A neutrophil count 
<0.5×109/L is considered severe neutropenia, which highly increases the risk of acquiring severe 
bacterial infections (69). Moreover, radiation therapy and chemotherapy damage the epithelial 
barrier, which increases the risk of bacterial translocation from the intestines. Altogether, these 
different mechanisms put children under treatment for malignancies at high risk of severe 
blood stream infections, i.e. sepsis or septicemia. The signs of illness are often discrete owing to 
the immune suppression hampering the inflammatory response. Fever is sometimes the only 
objective symptom of septicemia. For these reasons, treatment with broad-spectrum antibiotic 
therapy is started immediately in children with neutropenia during febrile episodes. This 
strategy, together with an improved chemotherapy have contributed to a remarkable increase in 
5-year survival in pediatric malignancies over the last decades (71). Nevertheless, long courses 
of broad-spectrum antibiotics negatively affect the children in many ways, such as disturbing 
the gut microbiota, and increasing the risk for hospital-acquired infections. Moreover, in the 
majority of cases, no causative agent can be found (72). As RTIs are common in children in 
general, it is likely that they also play a significant role in febrile episodes in children under 
treatment for malignancies. Accurate diagnostics to distinguish between harmless viral 
infections and life-threatening bacterial infections are needed to reduce the high antibiotic 
pressure in this group.  
 
 
1.2 RESPIRATORY PATHOGENS 
Viruses are small (20-300 nm) infectious agents completely dependent on the cellular 
machinery of other organisms to successfully replicate (73). They consist of a small genome 
sequence packed inside a protein shell sometimes surrounded by an envelope, a lipid 
membrane. Viruses infect most known organisms including plants, animals and other 
microorganisms. They are classified according to their genome into DNA-viruses and RNA-
viruses. More than 300 different virus serotypes have been associated with respiratory disease in 
human (table 3), of these, several have been discovered during the last two decades owing to 
molecular-based methods with increased sensitivity (figure 4). The infectious focus of 
respiratory viruses is usually less distinct as compared to bacterial infections. Consequently, the 
distinction between viral URTI and LRTI is sometimes delicate. 
 
 
Figure 4. Year of Discovery for Respiratory Viruses Pathogenic to Human.  
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Table 3. Respiratory Viruses Pathogenic to Human 
Virus species  
(family) 
Structure Subtypes 
Incubation 
period (74) 
Associated diseases 
Adenovirus 
(Adenoviridae) 
DNA 
non-enveloped, 
icosahaedral  
52 serotypes 
within the 
groups A-G 
4-6 days 
Tonsillitis,  
common cold, 
pneumonia, 
gastroenteritis, 
influenza-like illness. 
Bocavirus 
(Parvoviridae) 
DNA 
non-enveloped, 
icosahaedral 
1-4 unknown 
Common cold, 
bronchiolitis. 
Coronavirus 
(Coronaviridae) 
RNA+ 
enveloped, 
helical 
NL63, OC43, 
HKU1, 229E, 
MERS, SARS 
3-4 days 
Common cold, 
SARS, MERS. 
Enterovirus 
(Picornaviridae) 
RNA+ 
non-enveloped, 
icosahaedral 
≥67 serotypes 
within the 
subgroups A-D 
3-6 days 
Common cold, 
meningitis, hand-foot 
and mouth disease, 
systemic disease. 
Influenza virus 
(Orthomyxovirus) 
RNA- 
enveloped,  
segmented 
A-C 1-2 days 
“Influenza”, 
encephalitis, 
gastroenteritis, myositis, 
pneumonia. 
Metapneumovirus 
(Paramyxoviridae) 
RNA- 
enveloped 
A and B 3-6 days 
Bronchiolitis, 
pneumonia, common 
cold. 
Parainfluenza virus 
(Paramyxoviridae) 
RNA- 
enveloped 
1-4 2-3 days 
Viral croup, common 
cold, bronchiolitis, otitis 
media, pneumonia. 
Respiratory syncytial 
virus 
(Paramyxoviridae) 
RNA- 
enveloped 
A and B 4-5 days 
Bronchiolitis, common 
cold, otitis media, 
pneumonia. 
Rhinovirus 
(Picornaviridae) 
RNA+ 
non-enveloped, 
icosahaedral 
>100 serotypes 
within the 
subgroups  
A-C 
1-2 days 
Common cold, 
bronchiolitis, 
(pneumonia). 
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1.2.1 DNA-Viruses 
DNA-viruses are genetically stable viruses that usually cause a low-grade persistent infection 
(73). Some DNA viruses cause latent infections that persist for years. DNA-viruses replicate in 
the nucleus. 
 
 
1.2.1.1 Adenovirus 
Human adenovirus (HAdV) was isolated from adenoid and tonsil tissue in 1953 (75). It was 
initially considered to be the “virus of the common cold” yet today we know that the virus is 
capable of infecting several organ systems, the two most common being the respiratory and the 
gastrointestinal tract. Tissue tropism partly correlates with specific serotypes (76). The virus is 
largely genetically conserved with a low mutation rate, instead, it escapes the immune system by 
causing chronic low-virulent infection and a large proportion of asymptomatic children are 
positive for adenovirus in their upper-respiratory tract (55,75,77–80). In contrast, acute HAdV 
infection is characterized by sore throat, high-grade fever, malaise, runny nose, conjunctivitis 
and diarrhea (76). The virus is also associated with severe LRTI and has been identified in lung 
tissue of deceased children with CAP (81,82). HAdV is capable of eliciting a substantial 
inflammatory response, thus mimicking bacterial infection in terms of CRP levels and white 
blood cell counts (83). This is one of the reasons for the frequent use of HAdV vectors in 
vaccine development. Systemic HAdV infection causing multi-organ failure is a major concern 
in immunosuppressed patients following organ transplantation (76). 
 HAdV is an extremely stable virus, highly resistant to drying, proteases in the 
gastrointestinal tract and even to most detergents (76). The incubation period is 5-6 days and 
outbreaks are relatively common (74,84). An oral vaccine against HAdV type 4 and 7 is 
estimated to prevent 13.000 episodes of febrile illness in US military recruits annually but is 
currently not used in civilian populations (84). The antiviral drug cidofovir is used in stem-cell 
transipients with severe HAdV infection and novel treatment strategies are in the pipeline (76).  
 
 
1.2.1.2 Bocavirus 
Bocavirus (HBoV) is a small single-stranded DNA virus in the parvoviridae family that was 
discovered by researchers at Karolinska Institutet in 2005 (5). The virus has been associated 
with both URTI and LRTI but is predominately detected in combination with other respiratory 
viruses and is also frequently detected in asymptomatic children (13,55,85,86). Whether the 
virus is a true human pathogen or merely a bystander is debated (87). HBoV single infection 
with high titers has been reported in children with severe respiratory tract infection suggesting a 
causal relationship (88). 
 
 
1.2.1.3 Other DNA-Viruses 
Polyomaviruses WU and KI are increasingly being recognized as respiratory viruses pathogenic 
to human (89). Some viruses in the herpesviridae family can present with respiratory symptoms 
(90). 
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1.2.2 RNA-Viruses 
In contrast to the genetically stable DNA-viruses, RNA-viruses evade the immune system by 
constantly mutating. This is maintained by the unstable nature of the RNA and the lack of 
proofreading systems of the replication product. RNA-positive viruses have a similar 
configuration as the human messenger RNA and injection of the genetic material into the cell is 
sufficient for establishing infection (73). These viruses are usually non-enveloped and highly 
resistant to detergents. In contrast, the RNA-negative viruses need to be converted by a non-
human enzyme carried by the virion (RNA-dependent RNA polymerase) prior to replication. 
For this reason, all RNA-negative viruses are enveloped making them more sensitive to drying 
as well as to ethanol and detergents. 
 
 
1.2.2.1 Coronavirus 
Human coronavirus (HCoV) is an enveloped RNA-positive virus that was discovered in the 
early 1960s (91). Despite being enveloped, the virus is capable of enduring the extreme 
environment of the gastrointestinal tract. There are six known species including SARS and the 
recently discovered Middle East Respiratory Syndrome (MERS). HCoV infection has an 
incubation time of 3-4 days and, with the exception for SARS and MERS, associated with a mild 
respiratory disease. In contrast, the novel strains SARS and MERS are highly pathogenic and 
caused outbreaks of atypical CAP with significant mortality among health care workers during 
2003 and 2014 (24,92).  
 
 
1.2.2.2 Enterovirus 
Enterovirus (EV) is a non-enveloped RNA-positive virus within the picornaviridae family 
closely related to rhinovirus. There are four different species known to cause disease in human: 
A, B, C and D (93). The disease pattern is widespread, ranging from mild common cold, hand, 
foot and mouth disease, pleuritis and gastroenteritis to severe encephalitis, meningitis and 
myocarditis (93,94).  Several outbreaks of highly pathogenic enteroviruses have been reported 
including the EV-D68 outbreak in 2014 causing severe respiratory disease with significant 
mortality and the EV-A71 outbreak of hand, foot and mouth disease in 2016 with severe 
neurological complications (95,96). A vaccine against enterovirus 71 was recently evaluated in a 
Phase III trial in China with reportedly good protection against hand, foot and mouth disease as 
well as against neurological complications (97).  
 
 
1.2.2.3 Influenza virus 
Influenza virus is an enveloped segmented RNA-negative virus that was first recovered 1933 
(98). As opposed to other RNA-viruses, influenza viruses replicate in the cell nucleus. There are 
three types of influenza virus causing disease in human (A, B and C). Influenza A is a zoonotic 
and highly pathogenic virus (99). Influenza B is associated with similar symptoms as type A but 
does not cause pandemics. The incidence of influenza B is currently increasing in Swedish 
children (100). Influenza C is less pathogenic and associated with mild respiratory disease (101).  
Characteristic influenza symptoms are rapid onset of fever, malaise, joint pain and cough. 
Atypical presentation such as febrile seizures or gastroenteritis is common in children (102). 
Influenza has been associated with CAP both as a primary pathogen and by predisposing for 
secondary bacterial infection (101). A large study in the US reported positive bacterial blood 
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cultures in only 2% of children hospitalized with influenza (3% in the subgroup of influenza 
positive children with a discharge diagnosis of CAP) indicating that severe secondary bacterial 
infections are rare (101). Other complications include otitis media, myocarditis, dehydration 
and encephalitis.  
The incubation period is 0-2 days and transmission is mainly airborne (74). Aerosol 
transmission is facilitated in cold and dry climate, which is one reason for the seasonal influenza 
epidemics during winter (103). The virus is rapidly cleared from the respiratory tract after 
recovery and detection in asymptomatic children is uncommon (56,58,59). Nevertheless, large-
scale serologic studies have suggested that a significant proportion of influenza virus infections 
are asymptomatic (104). Immunity is acquired after infection, but the virus is constantly 
mutating (antigenic drift), which allows individuals to be reinfected every year (73). Genetic 
segment reassortment of genes encoding the proteins hemagglutinin and neuraminidase is 
unique for influenza A and can occur when two different strains co-infect the same cell 
(antigenic shift) (105). By remodeling these two surface proteins, the virus efficiently evades 
herd immunity. Such novel influenza strains have caused several devastating pandemics 
throughout history (table 4). 
 
Table 4 –Historical Influenza Epidemics and Pandemics 
Influenza A strain Pandemic/epidemic (year) Comment 
H1N1 
 
 
 
 
 
 
Spanish flu (1918-1920)  
 
 
Swine flu (2009-2010) 
Pandemic spread. Associated with 
20-100 million deaths globally. 
 
Pandemic spread. Associated with 
18.000-250.000 deaths (106). 
Highest attack rate in adolescents. 
H2N2 
 
Asian flu (1957-1958) 
 
Pandemic spread. Associated with 
1-1.5 million deaths globally. 
H3N2 
 
Hong Kong flu (1968-1969) 
 
Pandemic spread. Associated with 
0.75-1 million deaths. 
H5N1 
 
 
Avian flu (1997-2011) 
 
 
Bird flu. No human-human 
transmission. Sporadic cases, 
mortality rate 50-70%. 
 
 
Two antiviral drugs are approved for use in children, the orally administered oseltamivir 
(Tamiflu®) and the inhaled drug zanamivir (Relenza®). Both act as neuraminidase inhibitors 
which prevents the virus at the release stage, i.e. as they detach from the infected cells. 
Treatment with first generation neuraminidase inhibitors has been shown to shorten the 
clinical course with approximately one day and the best effect is achieved if treatment is started 
≤12 hours after onset of fever (107,108). Seasonal influenza vaccines are developed annually and 
recommended to all children ≤5 year by the WHO (109). The evidence for these 
recommendations is weak and only a few countries have implemented this, including the US, 
the UK and Finland. The European council recommend immunization of certain high-risk 
groups (110).  
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1.2.2.4 Metapneumovirus 
Human metapneumovirus (hMPV) is an RNA-negative virus in the paramyxoviridae family 
that was first described in 2001, however, serological analyses indicated that the virus had been 
circulating in humans for at least half a century (3). There are two genotypes (A and B) with a 
similar clinical presentation (111). The virus is closely related to RSV and has been associated 
with URTI, bronchiolitis, and CAP (13,58,112–114). It attributes to significant morbidity in 
young previously healthy children (115). In immunocompromised children, hMPV might 
progress to severe LRTI particularly in hematopoietic stem cell transplantation recipients (116). 
The virus usually follows an epidemical pattern in temperate countries, increasing in winter and 
spring with a largely varying incidence between years (114). Supportive care with oxygen, 
parenteral fluids is sometimes necessary for severe cases (50). Ribavirin and intravenous 
immunoglobulin have been used experimentally against hMPV CAP (117). No vaccine is 
available, but there are several ongoing vaccine projects at a pre-clinical stage (118). Detection 
of hMPV in asymptomatic children by PCR is uncommon (115). 
 
 
1.2.2.5 Parainfluenzavirus 
Parainfluenzavirus (PIV) is an RNA-negative virus in the paramyxoviridae family, that was first 
described in 1956 (119). Four subtypes (1-4) cause disease in human. PIV1 and PIV2 are the 
two most common cause of viral croup accounting for approximately two-thirds of all cases 
(120,121). Other manifestations include common cold and bronchiolitis. The virus has also 
been associated with CAP but the true causative role is not fully understood (55,56). No current 
treatment is available but antivirals specifically targeting PIV as well as vaccines are under 
development, although at an early experimental stage (122,123).  Detection of PIVs in 
asymptomatic children is uncommon (13,124).  
 
 
1.2.2.6 Respiratory Syncytial Virus 
RSV is an enveloped RNA-negative virus in the family paramyxoviridae that was first 
discovered in 1956 (125). The virus follows an epidemic pattern in temperate countries and is a 
large burden on pediatric hospitals during the peak in the late winter months (126). For reasons 
not fully understood, the RSV epidemic usually have a regular biannual pattern in the 
Scandinavian countries, with an early intensive epidemic the first year followed by a late and 
less intensive epidemic the next year (127,128). The phenomenon has been suggested to be due 
to viral interference, but is likely also partly explained by herd immunity (127,128). 
RSV infection mostly presents as a common cold infection, however, it is also the most 
common cause of bronchiolitis and viral CAP (126). Infancy, prematurity, chronic underlying 
conditions and immunosuppression are risk factors for severe disease and early RSV infection 
has been associated with the development of asthma (129). RSV CAP in immunosuppressed 
stem-cell recipients is associated with extensive mortality (130). Mutations in toll-like receptor 4 
have been associated with severe disease (131). RSV bronchiolitis usually starts with 3-4 days of 
rhinorrhea and low-grade fever slowly progressing to severe breathing difficulties, increased 
mucus production, cough, wheezing, retractions and tachypnea (50). The characteristic clinical 
presentation is usually enough for a clinical diagnosis during the peak of the outbreak but 
should be confirmed by rapid antigen testing or PCR off-season and in atypical cases. 
Pathogenesis is related to an excessive local immune response with massive infiltration of 
neutrophils in the lumen causing edema and bronchoconstriction and the virus evades the 
immune system via inhibition of type-1 interferon (132,133). Hospitalization and supportive 
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treatment with nutrition, oxygen supplementation, inhalation therapy with hypertonic saline 
and even mechanical ventilation or BiPAP/CPAP are necessary in some cases (134). Inhalation 
of epinephrine and salbutamol are no longer recommended by the American Academy of 
Pediatrics due to lack of evidence (48). Apnea is a rare complication to RSV infection where the 
pathogenesis is not fully understood (133). Protective antibodies are seldom acquired after 
infection and the virus is able to reinfect the same individual several time throughout life 
without undergoing antigenic change (135). Palivizumab (Synagis®) is a humanized monoclonal 
antibody directed against the F-protein of RSV that is used as prophylaxis in children at high 
risk for severe RSV infection. Current guidelines from the American Academy of Pediatrics 
recommend palivizumab during the first year in preterm children with chronic lung disease and 
in extremely preterm children (136). A randomized controlled trial on healthy preterm infants 
reported a significant lower number of wheezing episodes during the first year of life in children 
treated with palivizumab as compared to the placebo group (46). 
After some major drawbacks including an early trial in the 1960s where a live-attenuated 
vaccine candidate caused lethal infection in two children, there are currently several ongoing 
vaccine projects ranging from early experimental studies to a Phase III clinical trial (Novavax®) 
(133,137). Maternal immunization is an alternative strategy to immunizing the children, as 
maternal antibodies transfer through the placenta and infants are at highest risk for severe 
infection (133).  
 
 
1.2.2.7 Rhinovirus 
Human rhinovirus (RV) is a non-enveloped RNA-positive virus that was discovered in 1956 
(138). The genome resembles the human messenger RNA. There are more than 100 different 
serotypes described, divided into three groups: A, B and the recently discovered C (139). RV is 
the most common cause of URTI in both children and adults (24). Infection usually present as a 
mild, self-limiting “common cold” with runny nose, cough, rarely persisting more than 1-2 
weeks (73). Immunity is evaded by frequent mutations and a large number of serotypes, hence 
preschool children commonly acquire serial RV infections during the winter season. RV-A and 
RV-C have been reported to be more pathogenic as compared to RV-B, but the difference does 
not appear to be extensive (140–142). Wheezing is a common symptom in toddlers and 
asthmatic children with RV infection, but the causal relationship between RV and asthma is 
debated (143). Certain single nucleotide polymorphisms have been linked to increased risk of 
RV wheezing indicating a genetic rather than environmental relationship (144). 
RV is detected throughout the year, in the northern hemisphere the highest levels are 
observed in fall, preceding the yearly RSV and influenza epidemics (145). The non-enveloped 
structure makes the virus stable and resistant to drying as well as to many detergents. The virus 
is transmitted through fomites, i.e. contaminated objects such as hands but also spread as 
aerosols (73). RV replicates more robustly in epithelial cells at low temperatures, partly due to 
decreased antiviral activity of the innate immune system, which lends some support to the 
historical belief that low temperature causes common cold (146). 
The novel antiviral pleconaril has shown to moderately alleviate symptoms and shorten 
disease duration of RV infection in adults but is not approved for use in children (147). RV is 
commonly identified in children with severe RTIs such as influenza-like illness and CAP but the 
causal relationship is debated as the virus is frequently detected in asymptomatic children 
(27,80,124,148–150). 
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1.2.2.8 Other RNA-Viruses 
Many viruses that cause systemic infection, such as measles and hantavirus, can present with 
respiratory symptoms but are not further discussed in this thesis (90). 
 
 
1.2.3 Gram-Positive Bacteria 
Gram-positive bacteria commonly reside in the skin, as well as in the respiratory tract. They 
have a thicker cell wall as compared to Gram-negative bacteria, which absorbs the legendary 
Gram-stain that is still frequently used in hospital laboratories for diagnostic purposes (73). 
 
1.2.3.1 Streptococcus pneumoniae 
S. pneumoniae or pneumococcus, is an extracellular Gram-positive diplococcus known to 
mankind since the late 19th century (73). It has several virulence factors including a 
polysaccharide capsule, pili and hydrolytic enzymes located in the cell wall (151). S. pneumoniae 
is the most common cause of bacterial CAP, septicemia and meningitis in children and 
attributes to approximately 800.000 deaths in children below 5 years annually (152). Typically, 
pneumococcal CAP is characterized by rapid onset of fever and shortness of breath; coughing is 
not always present as there are only few cough receptors in the alveoli (153).  
Colonization of the upper respiratory tract is common in children, seen in approximately 25-
80%, with higher rates in low- and middle-income countries (59,9). Colonization of S. 
pneumoniae is maintained by adhesion to epithelial cells through certain cell-wall associated 
proteins, whereas the polysaccharide capsule surrounding the bacteria protects from 
phagocytosis (8). Acquisition is usually not associated with symptomatic infection but seems to 
be facilitated by certain viral infections (154). Passive smoking and maternal pneumococcal 
carriage are other factors associated with colonization (154,155). S. pneumoniae is mainly 
transmitted horizontally via droplets and aerosols (155).  
 
 
Table 5 –Pneumococcal Serotypes Targeted by Vaccines 
Vaccine Serotypes covered Comment 
PCV7 (Prevenar 7®) 4, 6b, 9V, 14, 18C, 19F, 23F conjugate vaccine 
PCV10 (Synflorix®) serotypes in PCV7 + 1, 5, 7F conjugate vaccine 
PCV13 (Prevenar 13®) serotypes in PCV10 + 3, 6A, 19A conjugate vaccine 
PPSV23 (Pneumovax®) 
serotypes in PCV10 + 2, 3, 8, 9N, 10A, 
11A, 12F, 15B, 17F, 19A, 20, 22F, 33F 
polysaccharide vaccine 
 
 
Invasive pneumococcal disease (IPD) is defined as detection of S. pneumoniae in normally 
sterile anatomical locations such as blood and cerebrospinal fluid (155). As colonization is a 
prerequisite for invasive disease, reducing the pneumococcal carriage in children has been a 
major public health goal during the last decades (155). There are more than 90 different 
capsular serotypes of the bacteria described, some are highly associated with invasive disease 
(155). These have been targets for pneumococcal vaccines (table 5). Immunization with 
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pneumococcal conjugate vaccine (PCV) have been successfully introduced to most parts of the 
world during the last 10 years and contributed to a declining incidence of IPD, as well as of 
sinusitis and CAP (156). In 2015, there were n=23 laboratory confirmed cases of IPD in 
Swedish children <5 years, the most common serotypes being 3, 22F and 19A (157). In Sweden, 
the 13-valent vaccine, PCV13, is most widely used (given to approximately 56% of all Swedish 
children) followed by PCV10 that is provided in certain Swedish counties  (157). Despite a 
decline in invasive pneumococcal serotypes associated with the vaccination, the carriage rate 
has remained constant due to replacement of non-vaccine types (9). The 23-valent 
polysaccharide vaccine (Pneumovax®) has shown to have limited immunogenicity in young 
children and is currently only recommended to children >2 years at high risk of infection (158). 
Notably, PCV10 uses Haemophilus influenzae Protein D as one of the conjugate proteins, which 
seems to provide some protection against non-typeable H. influenzae (159). 
 
 
1.2.3.2 Staphylococcus aureus 
S. aureus is a Gram-positive coccus that is a common colonizer of the skin as well as of the 
respiratory tract (160). Once penetrating the epithelial barriers, the bacteria is capable of 
causing severe infections including abscesses, necrotizing CAP and septicemia (161). Infants 
and neonates are at highest risk for invasive disease (161). The pathogen is also a common cause 
of nosocomial i.e. hospital-acquired pneumonia in children but the role of CAP seems to be 
limited (18). Meticillin-resistant S. aureus (MRSA) is a large burden on the health care system 
and outbreaks in neonatology units are common globally, although not yet in Sweden 
(162,163).  
 
 
1.2.3.3 Other Streptococci 
S. pyogenes or Group A streptococcus (GAS), is a Gram positive coccus associated with skin 
infections as well as predominantly upper RTIs including pharyngotonsillitis, sinusitis, acute 
otitis media and mastoiditis (164). It is also a rare cause of necrotizing CAP (165). In contrast to 
GAS skin infections that commonly progress to septicemia, the risk for invasive disease in GAS 
associated pharyngotonsillitis is low (164). Group B streptococci is the most common cause of 
neonatal septicemia (166). Group C and G streptococci are less common causes of 
pharyngotonsillitis (73). 
 
 
1.2.4 Gram-Negative Bacteria 
Gram-negative bacteria have a thinner, and more complex cell wall as compared to Gram-
positives, and are, in general, less susceptible to penicillins (73). 
 
1.2.4.1 Haemophilus influenzae 
H. influenzae is a small Gram-negative coccobacillum that was believed to be the cause of 
influenza prior to the discovery of the influenza virus in 1933 (98). H. influenzae is associated 
with a wide range of infections in the respiratory tract. The most important virulence factor is 
the carbohydrate capsule, which aids in evading the immune system by preventing from 
opsonisation and phagocytosis (167). Classification of the bacteria can be made based on the 
capsular structure into six serotypes (A-F). An efficient conjugate vaccine against the highly 
invasive H. influenzae type B (Hib) is available and has almost eradicated Hib meningitis and 
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epiglottitis in high-income countries (168). Nevertheless, in the year 2000, Hib still attributed to 
an estimated 371.000 deaths in children <5 years due to insufficient vaccination coverage (169). 
Non-typeable H. influenzae are increasingly being recognized as important pathogens in 
children (167). H. influenzae was the second most common cause of CAP in the early lung-
aspirate studies from the pre-Hib-vaccination era (170). The current prevalence of H. influenzae 
in childhood CAP is largely unknown. Invasive cases are rare in Swedish children, with n=12 
laboratory confirmed cases in children 0-4 years in 2015 (157). 
 
 
1.2.4.2 Other Gram-Negative Bacteria 
Moraxella catharralis seems to be an infrequent cause of CAP in children (171). The anaerobic 
bacterium Fusobacterium necrophorum is a rare, but likely underdiagnosed, cause of unilateral 
pharyngotonsillitis (35). 
 
 
1.2.5 Atypical Bacteria 
Bacterial causes of CAP, other than S. pneumoniae and H. influenzae, have historically been 
referred to as atypical bacteria, given that they usually have a milder disease presentation and 
only respond to certain classes of antibiotics (73).  
 
 
1.2.5.1 Bordetella pertussis 
Whooping cough is an infection in the bronchi caused by the bacteria Bordetella pertussis and 
Bordetella parapertussis. The typical clinical presentation includes violent coughing attacks 
followed by characteristic whooping episodes and apnea. Recently, the bacteria have also been 
associated with CAP (59,172). Leukocytosis is a common laboratory finding (173). The bacteria 
are also infrequent findings in children with CAP and associated with poor outcome (59,172). 
Whooping cough can last for several weeks but children are usually well-appearing in between 
the attacks complicating the clinical diagnosis. Coughing is triggered by a bacterial toxin that 
can persist for a period of time after the bacteria have been cleared. Antibiotic treatment has 
limited effect on the clinical course but is commonly prescribed to limit the spread of the 
disease (174). Eleven deaths in previously healthy unvaccinated infants have occurred in 
Sweden between 2003-2016 and the incidence seems to be increasing again, albeit from low 
levels (figure 5) (175). The old whole-cell vaccine was removed from the immunization 
program in Sweden in 1979 and replaced by an acellular vaccine in 1996. Between these years, 
no vaccination against pertussis was carried and hence the current parental generation is largely 
unvaccinated (175). Induced sputum sampling seems to improve diagnostic sensitivity as 
compared to nasopharyngeal sampling (59,172). 
 
 
  29 
 
Figure 5. Incidence of pertussis in Sweden. Number of reported cases in Sweden. Data acquired from 
the Public Health Agency of Sweden. 
 
 
1.2.5.2 Legionella pneumophila 
Legionella pneumophila is an intracellular Gram-negative bacterium associated with severe 
respiratory and gastrointestinal disease (176). The name originates from a lethal outbreak of 
CAP in US military veterans and the disease is commonly referred to as Legionnaires’ disease 
(177). The bacteria grow in fresh water and several outbreaks associated with public swimming 
baths and cooling towers have been reported (176).  
 
 
1.2.5.3 Mycoplasma pneumoniae 
Mycoplasma pneumoniae is a bacterium that lacks a cell wall, which makes it resistant to beta-
lactam antibiotics (73). It is associated with atypical CAP, mainly in school-aged children (16). 
Extra-pulmonary symptoms such as headaches and arthralgia has been associated with the 
disease (153) as well as severe manifestation of mucositis and encephalitis (178,179). A 
prospective observational study by Spuesen et al assessed M. pneumoniae in children with RTI, 
as well as in asymptomatic hospital controls. They reported that detection of M. pneumoniae by 
culture, PCR and serology, i.e. current routine diagnostic tests, was inconclusive due to an 
equally high degree of positive results among the asymptomatic controls (65). 
 
 
 
1.2.6 Co-Infections and Viral Interference 
Every infection triggers an immune response in the host. It has been known for long that 
influenza infection is associated with an increased risk for bacterial CAP even after recovery, 
which was evident in 1919 during the Spanish flu (180). Studies on mice have indicated that this 
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could be mediated by a desensitization of TLR-5 ligands in the sentinel cells of the lung (181). 
Advancement in microbiological diagnostic methods have allowed for sensitive detections of 
multiple respiratory agents and viral co-infections are today frequent findings in children with 
RTI (13). However, the clinical significance of viral co-infections in RTI remains elusive (182).  
Viral interference refers to the interaction between virus outbreaks and has been reported 
between RSV and seasonal influenza (183). It is not clear whether this interaction takes place on 
a biological level (i.e. competition of target cells, upregulation of innate immunity etc) or on an 
epidemiological level (spreading patterns or behavioral differences). It was suggested that high 
levels of circulating RV hampered the spreading of the influenza A(H1N1)pdm09 (H1N1) 
pandemic in Sweden in 2009 (184). High levels of RV preceding the pandemic were also 
reported in Norway and France (185,186). Moreover, a retrospective study from Australia 
assessing respiratory specimens at the hospital laboratory reported that infection with RV was 
associated with a decreased probability of co-detection of other viruses (187). It is not fully 
understood whether this can be explained by a true causal relationship or whether it was just 
due to secular trends.  
 
 
1.2.7 Microbiological Diagnostic Methods 
There are several approaches to diagnosing infections (table 6). Some are directly targeted at 
detecting the pathogen (nucleic acids or cellular components) whereas others focus on the host 
response to an infection (serology, biomarkers). An optimal diagnostic test should have a high 
sensitivity and a high specificity. Sensitivity refers to the ability to correctly identify all patients 
with the disease i.e. to minimize the number of false negatives. Specificity refers to the tests 
ability to correctly identify patients without the disease i.e. high specificity indicates a low 
number of false positives. More importantly, the turnaround time is crucial for a test to play a 
role in clinical decision-making (16). Historical methods with slow turnaround times such as 
virus isolation and immunofluorescence microscopy have been replaced by faster and more 
sensitive molecular-based methods such as real-time polymerase chain reaction (PCR) (2). 
Electron microscopy still plays a role in detecting emerging pathogens (188). The technique has 
the advantage of visualizing unknown pathogens as opposed to PCR where the primers and 
probes have to be designed in advance based on already known motifs of the targeted microbes. 
Most point-of-care rapid tests are based on antigen detection and are in general less sensitive 
than PCR since they lack an amplification step. Next-generation sequencing (NGS) refers to 
different sensitive whole genome sequencing techniques that are increasingly being used in 
metagenomics, i.e. characterization of the complete genetic material in a sample. This approach 
has been used to discover several novel viruses (3,5,189). A disadvantage of all molecular-based 
methods is that the detections might reflect nucleic acid fragments rather than viable pathogens. 
Indeed many respiratory viruses have been shown to be frequent findings in asymptomatic 
individuals  (13,55,79,80,90,124,150,190). Serology has poor correlation to PCR for certain 
viruses such as HAdV but correlates better for influenza (191). 
Bacterial culture is an old but widely used method for detecting bacteria. The method also 
allows determination of antimicrobial resistance. Some bacteria are hard to culture and can only 
be identified by molecular-based methods. Moreover, the sensitivity of pediatric blood cultures 
is low. PCR-analysis of blood has been reported to improve sensitivity for detection of S. 
pneumoniae as compared to conventional blood cultures without compromising specificity, but 
is currently not used in the clinic (192). 
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Table 6. Microbiological Diagnostic Methods 
Method Application Comment 
Culture Widely used in clinic for 
common bacteria and fungi.  
Allows estimation of 
antimicrobial resistance. 
(Virus isolation) (Research) 
Slow turnaround time, not useful 
for several viruses. 
Electron microscope For research purposes and 
surveillance of emerging 
epidemics of unknown 
pathogens.  
Useful for new unknown 
pathogens. Visualize the 
structure of the pathogen. 
Immunofluorescence Research High turn-around time, user-
dependent. Visualize the 
structure of the pathogen. 
PCR Widely used in clinic for 
atypical bacteria, viruses. 
Sensitive method. Only detects 
fragment of the pathogen. 
Sensitive to mutations of primer 
and probe binding regions of the 
viruses. Cannot detect previously 
unknown pathogens. 
Next-generation sequencing 
(NGS) 
Research purposes 
Sensitive method. Creates large 
amount of data. Hard to evaluate 
the clinical significance. Slow 
and expensive. 
Antigen tests 
(immunochromatographic tests) 
Rapid tests for influenza A, 
RSV, GAS etc. 
Rapid method. Limited 
sensitivity. 
Serology Severe atypical infections. 
Research 
Detects the antibody response of 
the host. Sensitive, but slow 
turnaround time. Limited 
specificity due to cross-reactivity. 
Microarray analyses (biochip) Future method? Allows detection of a very large 
number of pathogens.  
Mass spectrometry Research Can be combined with nucleic-
acid amplification methods as in 
the commercial pathogen 
identification system IRIDICA® 
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1.3 EPIDEMIOLOGY 
1.3.1 Study Designs 
Epidemiology is the core science of public health, but epidemiological methods and critical 
thinking can apply to most sciences. In the field of epidemiology, the main aim is usually to 
study the association between different exposures with a predefined disease or outcome. 
Different study design can be used depending on the research question. Experimental studies, 
mainly randomized controlled trials, are considered to yield the highest degree of evidence but 
are seldom feasible to conduct due to practical and ethical restrictions. For that reason, 
observational studies are often the only feasible alternatives. The two most common types of 
observational studies are cohort studies and case-control studies. In a cohort study, a defined 
population is followed until they eventually develop the predefined outcome. In case-control 
studies a reverse approach is used, where cases, with the outcome of interest, and controls, 
without the outcome, are identified and then assessed with regard to exposure. 
 
 
1.3.2 Chance and Random Error 
In every comparative analysis, there is a possibility that any potentially observed difference 
between two groups for a certain statistic was there just by chance. There are several statistic 
methods to handle this depending on the nature of the data (continuous or categorical, 
dependent or independent etc). Usually, confidence interval and p-values are calculated to give 
an estimate of the precision of the statistic or the point estimate based on the variance in the 
observations. Confidence intervals are commonly set at 95% corresponding to a p-value of 
<0.05. This means that the p-values are considered significant if we can be ≥95% sure that the 
observed effect is not there just by chance (assuming there is no bias in the study). Multiple 
testing violates this assumption. If twenty different tests are run in a study, one should be 
statistically significant just by chance, which is referred to as type-I error. In contrast, type-II 
error is related to the risk of rejecting a true effect due to a non-significant p-value. This risk is 
associated with the confidence level but also dependent on the study size and power. 
Despite efforts in the study design, most studies will have some degree of random error, such 
as measurement errors, typing mistakes etc. These might increase the variance and negatively 
affect the precision of the study.  
 
 
1.3.3 Bias 
If the errors in a study do not occur at random, they are considered systematic errors or bias. 
This is a much more serious concern and directly affect the validity of the study. Bias has been 
categorized into three major groups: selection bias, information bias and confounding. 
Selection bias refers to a systematic error in selecting study subjects. If study participants differ 
from non-participants in terms of exposure and outcome the estimated association will be 
skewed if the study population is compared to the general population. Accordingly, it is 
important in case-control studies that controls are selected to be representative of the cases. 
Information bias includes misclassification of study variables or outcomes, which can be non-
differential or differential depending on whether the misclassification is related to another study 
variable or not. Confounding refers to the confusion of effects. A confounder is a factor 
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associated with both the exposure and the outcome. An example would be smoking if one were 
to study the association between alcohol consumption (exposure) and lung cancer (outcome). 
Given that smoking is a verified cause of lung cancer and that it is possible that smoking is more 
common in individuals with high alcohol consumption, the association between alcohol 
consumption and lung cancer would be confounded by smoking. Such a study would need to 
control for smoking not to overestimate the association between alcohol and lung cancer. There 
are statistical methods to handle confounding, yet residual, unmeasured or uncontrolled 
confounding are always concerns in observational studies.  
 
 
1.3.4 Infectious Disease Epidemiology 
Some concepts in infectious disease epidemiology are unique for the field and for that reason, 
worth some extra attention. When studying diseases with human-human transmission one has 
to be aware that a case can also be an exposure i.e. cases can give rise to secondary cases. The 
basic reproductive number, R0, is a measure of the average number of persons infected by a case 
in a totally susceptible population. This is dependent on how contagious the pathogen is, but 
also on the route of transmission, the number of contacts and duration of the infectious period. 
The R0 is in general enhanced if the incubation period is shorter than the latency period, i.e. the 
infected individuals are infectious before they develop symptoms. If R0 >1 there is a risk that the 
pathogen will cause an epidemic. The fact that some individuals are usually immune to a certain 
disease will also affect the spreading patterns. The immunity on a population level is referred to 
as herd immunity and is of great importance for preventing disease outbreaks. The level of 
required vaccination coverage for preventing outbreaks is related to the R0 of the disease. B. 
pertussis has a high R0 whereas influenza is less contagious, for that reason, a vaccination 
coverage of 50-76% is needed to prevent influenza outbreaks whereas B. pertussis requires a 
higher coverage, approximately 92-93% (193,194). 
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2 AIMS 
The general objective of this thesis is to improve the current knowledge of the causative role of 
respiratory microbes, predominantly viruses, in children with severe RTI with the long-term 
goal to reduce unnecessary antibiotic use in this patient group. This is important both in the 
general pediatric population, as well as in vulnerable populations, such as children with 
malignancies, to improve future preventive and treatment measures. To reach this goal a 
number of basic concepts must be clarified as defined by a number of specific aims. 
 
 
2.1 PRIMARY AIMS 
§ To assess respiratory viruses in children with influenza-like illness  
 
§ To define the viral etiology of acute respiratory illness in children  
 
§ To define the viral etiology of community-acquired pneumonia in children 
 
§ To investigate the role of respiratory viruses in febrile neutropenia in children 
 
 
2.2 SECONDARY AIMS 
§ To assess viral interference and the clinical impact of viral co-infection 
 
§ To investigate the clinical significance of PCR-positivity for respiratory viruses  
 
§ To characterize the clinical presentation of specific respiratory virus infections 
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3 METHODS 
The rationale behind the choice of study designs as well as a brief summary of the methods is 
described below. Detailed information can be found in the Materials & Methods sections of the 
respective articles. 
 
 
3.1 STUDY POPULATIONS 
An overview of the study populations is presented in figure 6. In Paper I, children <18 years 
with influenza-like illness (ILI) admitted to inpatient care at Astrid Lindgren Children’s 
Hospital during the H1N1 pandemic (July –December 2009) were retrospectively investigated. 
The policy of the hospital during the pandemic was to perform PCR-based influenza 
diagnostics on all children with suspicion of influenza infection. For this reason, the study 
provided a rather complete picture of severe respiratory infections among the childhood 
population in Northern Stockholm. To ascertain independency between the observations, only 
the first episode was included for children hospitalized multiple times during the study period. 
Paper II and Paper III were two matched case-control studies. This particular study design 
was chosen as detection of respiratory viruses by PCR was increasingly reported in 
asymptomatic children questioning the clinical significance of PCR-positivity (80,150). For this 
reason, we believed that representative controls would be of great importance for studies on 
RTIs in children. The two studies were not typical epidemiological case-control studies that are 
usually retrospective, register-based and designed to identify risk factors for rare diseases. 
Instead, the studies were predominantly prospective, the outcomes were rather common and 
the disease had a short induction period. Cases were prospectively enrolled at Sachs’ Children 
and Youth Hospital and Astrid Lindgren Children’s Hospital, Huddinge. Inclusion criteria were 
age <5 years and acute respiratory illness (ARI) defined as the presence respiratory symptoms 
(≥1 of runny nose, sore throat, earache, cough, sputum production or dyspnea) (Paper II) or 
age <5 years and CAP based on radiological findings (Paper III).  
Cases could only be enrolled once in the independency reasons. Healthy controls were 
enrolled by two research nurses at twenty-three different children health centers in Stockholm 
county during visits for vaccination and routine clinical check-ups (9). Information on 
socioeconomic status, co-morbidities and immunization status were collected for all study 
subjects using a standardized questionnaire. Controls with reported respiratory symptoms ≤7 
days were excluded in Paper II since they otherwise potentially would have fulfilled the 
inclusion criteria for the cases. This exclusion criterion was not applied in Paper III in line with 
the study design of the large upcoming PERCH study (195). A major factor in case-control 
studies is the standardized and equal handling of cases and controls. Only a minority of 
children with respiratory symptoms are in the early phase of developing CAP and many 
pathogens can cause both mild URTI and CAP. By excluding controls with respiratory 
symptoms, the control group would be less representative of the source population from where 
the cases arise. I.e. they would likely be “too healthy,” and hence biasing the results toward an 
overestimation of the association.   
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Figure 6. Overview of study populations 
 
 
One (Paper II) or two (Paper III) controls were individually matched to cases on age (+/- 6 
months) and calendar time (+/- 14 days). Intervals were expanded to age +/- 12 months and 
calendar time +/- 30 days if no eligible controls were found. Microbiological sampling and 
radiological examinations as ordered by the treating physician were retrospectively collected for 
all cases from the medical records. Study periods were September 2011 – January 2012 for 
Paper II whereas inclusion continued until March 2014 for Paper III. No sampling was 
performed during summer.  
In Paper IV, children ≤18 years undergoing treatment for malignancies were included 
during episodes of febrile neutropenia (FN) at the childhood cancer unit Astrid Lindgren 
Children’s Hospital in Stockholm, Sweden during January 2013 and June 2014. We initially 
wanted to enroll asymptomatic controls with neutropenia in the study but this was not 
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practically feasible. Instead, a longitudinal design with follow-up samples was chosen. FN was 
defined as a body temperature of ≥38.5°C on one occasion or ≥38.0°C on two occasions at least 
60 minutes apart, combined with an absolute neutrophil count of either 0.5×109/L on one 
occasion or 1.0×109/L with a decline to less than 0.5×109/L over a subsequent 48-hour period. 
Patients could be enrolled multiple times if they experienced recurrent episodes of FN during 
the study period. 
 
 
3.2 SAMPLING 
In Paper I, all respiratory specimens routinely collected in the clinic were used in the analyses 
including naso- and oropharyngeal swabs/aspirates as well as tracheal and bronchoalveolar 
lavages from a minority of the patients. In Paper II-IV nasopharyngeal aspirate sampling was 
used for all study subjects. 
 
 
3.3 MOLECULAR ANALYSES 
3.3.1 PCR-Analyses 
PCR is a fast and sensitive method for detection of respiratory viruses. A drawback is that the 
method is susceptible to antigenic drift and also merely detect nucleic acid fragments rather 
than viable viruses. Samples were extracted and analyzed by PCR for 16 different viruses at 
Karolinska University Laboratory, Solna (196). Duplex PCRs were used for all virus except for 
RV, EV, HAdV and HBoV. Extraction controls (EV, HAdV, influenza A and RSV A and B) and 
PCR-controls for each virus were used. The method is best described as semi-quantitative given 
that it renders cycle-threshold (CT) values inversely related to the viral load. First, the PCR is 
developed to favor detection of a broad range of clones (by using wobble primers, etc.) rather 
than to perfectly fit a particular virus strain. Also, respiratory viruses, mainly RNA-viruses, have 
a high mutation rate, for this reason, the amplification will not be entirely logarithmic to allow 
for backward calculation to the original quantity. Moreover, the exact amount of the input 
sample was unknown and respiratory specimens are more sensitive to sampling bias than for 
instance blood. One way to overcome this would have been to analyze a house-keeping gene 
from respiratory epithelial cells as a reference, which was not done (197). Finally, the exact 
concentration of the PCR-controls was not known. Instead the CT-values were monitored and 
the run discarded if the CT-value deviated more than two standard deviations from the mean of 
previous runs. Due to cross-reactivity between RV and EV, some samples were further analyzed 
by an in-house PCR for EV (Paper II-III) (198). 
 
 
3.3.2 Genotyping  
In Paper IV, samples positive for RV and EV were sequenced (VP4/VP2 region). This had 
several advantages. First, it made it possible to distinguish between EV and RV accurately. 
Second, specific RV genotypes could be determined. Finally, cases with repeatedly RV-positive 
samples could be further assessed to make a distinction between virus persistence and new 
infections.  
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3.4 STATISTICAL ANALYSES 
Data were analyzed in Stata version 12 and R. Fisher exact test and chi-square test were used for 
comparisons of independent categorical data whereas Mann-Whitney U-test and student T-
tests were used for independent continuous data as appropriate. A p-value <0.05 was 
considered significant. In Paper II-III, McNemar’s test, paired T-tests and Wilcoxon signed-
rank test were used for matched group comparisons as appropriate. Moreover, multivariate 
conditional regression analyses were performed with group (case or control) as outcome 
variable and age, viral co-infections and socio-demographic parameters as predictors. In Paper 
III the unexpectedly high numbers of co-infections created numerous unique strata when 
adjusting for confounders resulting in large drifts of the odds ratios. For this reason, matching 
was broken and cases were instead group matched to controls on year (2011, 2012, 2013), 
season (Fall, Winter, Spring) and age (<1 year and ≥1 years) in the final analyses. In Paper IV, 
multiple episodes were recorded from some of the study subjects. Nevertheless, independence 
between the observations was assumed and ordinary non-parametric testing was performed, in 
line with previous studies in the field (199–201).   
 
 
 
3.5 ETHICAL CONSIDERATIONS 
All studies were approved by the Regional Ethical Review Board in Stockholm. In Paper I, 
consents could not be collected due to the retrospective study design. Nevertheless, only study 
variables relevant for the study were collected and results were only presented at a group level. 
In Paper II-IV written consents were collected from the parents to the study subjects. To 
minimize the violation of integrity, each study subject was assigned a unique study ID and the 
study key was available only to the primary investigators. The sampling methods that were used 
in the studies are standard procedures that in many cases would have been performed 
regardless of the study. Children in Paper II-III were given a small gift after sampling, but this 
was not announced until enrollment was completed. We believe that the benefit regarding 
increased knowledge about severe viral respiratory tract infections overweighed the slight 
discomfort for the children due to additional sampling.  
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4 RESULTS AND DISCUSSION 
 
4.1 VIRAL ETIOLOGY OF RESPIRATORY TRACT INFECTIONS 
In Paper I and Paper II, the viral etiology was assessed in children with ILI and ARI, i.e. 
children with suspected viral respiratory tract infection. In clinical practice, viral respiratory 
infections are rarely diagnosed, partly due to the lack of antiviral treatments but also due to lack 
of knowledge of disease presentation of specific respiratory viruses as well as of the clinical 
significance of PCR-positivity. For those reasons, a positive test result (perhaps with the 
exception of influenza and RSV testing) rarely alter the clinical management or 
recommendations given to the patients. Nevertheless, despite the lack of antiviral treatment 
alternatives, there is a benefit in accurately diagnosing the viral infection as this would improve 
prediction of the clinical course and infectivity as well as decrease overuse of antibiotics (190). 
The inclusion criteria used in the studies were broad; both children with URTI and LRTI could 
be included since inclusion was based on clinical symptoms rather than on radiologically 
verified location of the infection.  
 
 
4.1.1 Influenza-Like Illness (Paper I) 
In Paper I, only hospitalized children were included and as much as 48.6% suffered from an 
underlying chronic disease, representing a more vulnerable population than the general 
children population of Stockholm. Six children died during the study period; all had severe 
underlying chronic conditions. One or more viruses were detected in 61.6% of the cases. RV 
was the most common virus (detected in 28.1%) followed by H1N1 (16.5%) and PIV (6.6%) 
(figure 7). RSV and hMPV were rare, detected in 2.4% and 0.4% of the cases respectively. 
  
 
Figure 7. Respiratory viruses in children ≤18 years with influenza-like illness. 
Data presented as proportion of positive patients. Abbreviations: RSV, respiratory syncytial virus. 
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Since the focus of the study was on H1N1, the study period included the Fall and the early 
Winter months (no H1N1 was detected after December 31th, 2010). This partly explains the low 
numbers of RSV and hMPV, as these viruses, in the Northern hemisphere, usually circulate 
later during the respiratory season (145). The microbiological data from Paper I are somewhat 
hard to generalize to other settings as the swine flu pandemic struck countries differently 
depending on national immunization strategies, time of introduction and perhaps also 
depending on other local virus epidemics. Even in Europe, there was a high degree of 
heterogeneity in the number of cases (185,186,202). The study underscores the overlap in 
symptoms of different viral infections in the respiratory tract given that only a minority of the 
patients with ILI tested positive for H1N1. Descriptive data such as these, have a value regarding 
virus surveillance and to generate hypotheses. Nevertheless, a shortcoming of Paper I is the lack 
of controls as a reference group, which severely hampers the causal inference of the findings.  
 
 
4.1.2 Acute Respiratory Illness (Paper II) 
In Paper II, children with ARI were studied. The study population resembled the one in  
Paper I in that sense that the inclusion criteria were based on clinical symptoms. However, they 
represented a less severely ill population given that all patients in Paper I were hospitalized in 
contrast to merely 10% in Paper II. Thirty-percent of the children presented with fever, 33% 
had an increased respiratory rate and none died during the study period. They could best be 
described as having mild to moderately severe disease, representing the large proportion of 
patients seen at a pediatric emergency unit. In total, 151/209 (72.3%) cases tested positive for 
one or more respiratory virus. This is line with other similar studies with a reported detection 
rate of 72-75%, yet higher than in Paper I, likely owing to the age difference as viral infections 
are more common in young children (80,150). In line with Paper I, RV was the most 
commonly detected virus (detected in 47.9%) followed by HBoV, HAdV and PIV (figure 8). No 
influenza viruses were detected during the study period.  
 
 
Figure 8. Respiratory viruses in children ≤5 years with acute respiratory illness.  
PCR data of respiratory viruses detected in cases with acute respiratory illness (pink) and controls (green). 
Data presented as the proportion of positive patients. Abbreviations: RSV, respiratory syncytial virus. 
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4.1.2.1 Case-Control Analysis  
To be able to account for asymptomatic detection of some respiratory viruses, a case-control 
study design was used in Paper II with individually matched population-based asymptomatic 
controls. Of the controls, 35.4% tested positive for one or more virus. Conditional logistic 
regression analyses assessing the association between detection of specific viruses and ARI 
showed significant associations for PIV (odds ratio(OR)=16.0; 95% confidence interval  
(CI): 2.1-120.6), RSV (OR=11.0; 95% CI: 1.4-85.2), hMPV (OR=5.0; 95% CI:1.1-22.8) HBoV 
(OR=4.4; 95% CI:2.0-10.1), and RV (OR=3.5 95% CI: 2.2-5.6). Population-attributable 
proportions were calculated showing that 39% of all episodes in the cases could be attributed to 
RV. Detection of EV, HAdV and HCoV were not significantly associated with ARI 
underscoring the importance of proper controls in studies of RTIs in children. The clinical 
significance of PCR-positivity will be further discussed below (Results section 4.2.1).  
 
 
4.1.2.2 Potential Sources of Bias 
A significant limitation in Paper II is the lack of complete bacterial data. Bacterial infection is 
an obvious potential confounder in the study given that it is associated with the outcome 
(several bacteria can cause respiratory illness) and potentially also with the exposure (virus-
bacteria interactions have been reported and will be further discussed in the results section 
4.2.3). Additional bacterial analyses such as paired serology of common respiratory bacteria 
would have been valuable. However, there is currently no reliable methods for diagnosing 
bacterial upper respiratory tract infections and even with the most thorough bacterial diagnostic 
workup we would still not be able to distinguish between children with true viral respectively 
bacterial infections accurately.  
Selection of controls that are representative of the cases is crucial in case-control studies. In 
Paper II, controls were enrolled at 33 different child health units during routine visits and 
vaccination. As Sweden has a uniquely high vaccination coverage of the child immunization 
program (approximately 99,7%), we reasoned that this was a suitable site for enrollment of 
population-based controls (157). Nevertheless, certain subgroups within the community such as 
migrants and children in families that are skeptical to vaccines are less likely to visit the child 
health centers. As these children still would show up at the emergency unit in case of illness, this 
was a potential source of selection bias.  
Further, controls with respiratory symptoms ≤7 days were excluded since they otherwise 
potentially would have fulfilled the case definition. The downside of this was a risk of 
introducing bias. Respiratory symptoms were common in the children and almost 30% eligible 
were excluded as controls for this reason. If we, by doing this, selected a “too healthy” control 
population that differed from the cases with regard to exposure or host factors (such as 
immunity) this could potentially have biased the results to an overestimated association 
between respiratory viruses and ARI. Moreover, there is a risk that the exclusion of children 
with respiratory symptoms increased the proportion of children with other infections such as 
gastroenteritis. Some respiratory viruses, mainly adenovirus and enterovirus are associated with 
both respiratory disease and gastrointestinal symptoms. Consequently, this approach could 
have led to an underestimated association with ARI for these viruses, which is somewhat 
supported by the fact that we failed to detect a positive association with ARI for HAdV. 
Only one season was studied in Paper II, which is also a limitation when generalizing the 
findings to other settings as the incidence of many respiratory viruses is varying between 
seasons (203).  
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4.1.2.3 A Review of the Literature 
How do the results from Paper II agree with other studies in the field? Numerous case series 
have been published reporting descriptive PCR data of children with respiratory tract infection; 
nevertheless, only a limited number of studies with a proper reference group have assessed this 
association. Table 7 provides a list of case-control studies and studies with longitudinal 
sampling investigating viral etiology in acute respiratory illness in children. 
 
 
Table 7. Viruses Associated with Acute Respiratory Illness in Children from 
Longitudinal and Case-Control Studies using PCR 
Study 
Co
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Kusel et al,  
2007 (204) Australia 	 x	 	 n/a	 	 	 x	 x	 x	
van der Zalm et 
al, 2009 (79) 
The 
Netherlands 
	 	 	 n/a	 	 	 	 	 	
Singleton et al, 
2010 (205) 
US n/a	 x	 x	 	 	 x	 x	 x	 	
Jansen et al, 
2011 (80) 
The 
Netherlands 
	 	 x	 	 	 x	 	 x	 	
Iwane et al, 
2011 (140) 
US n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 x	
Rhedin et al, 
2014 (13) 
Sweden 	 	 	 x	 	 x	 x	 x	 x	
Chonmaitree et 
al, 2015 (12) 
US 	 x	 x	 	 x	 x	 x	 x	 x	
Byington et al, 
2015 (11) 
US 	 x	 	 	 	 x	 x	 	 	
“x” indicates a reported significant association with acute respiratory illness. 
Abbreviations: n/a, not assessed 
 
 
The data from Paper II to a large extent agree with other relevant studies in the field. Significant 
association with ARI have been reported for hMPV, PIV, RSV and RV in most studies (table 7). 
In contrast, the association with ARI for HBoV is debated (86). Although there is increasing 
evidence that the pathogen is capable of causing respiratory tract infection (88), current 
diagnostic method seems to be limited in diagnosing the pathogen, which will be further 
discussed below (Results section 4.2.1).  
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4.1.3 Community-Acquired Pneumonia (Paper III) 
4.1.3.1 A Need for New Studies on CAP Etiology 
In Paper III we specifically wanted to assess the role of viruses in childhood CAP for a number 
of reasons. First, the disease contributes to significant mortality and morbidity in children, 
second, CAP has traditionally been considered a bacterial disease and antibiotics is prescribed 
on wide indications but the two major bacterial causative agents have recently become the 
targets of vaccines, which has likely led to a relative increase of other etiologies including viruses 
(1,16). Given that the IMCI guidelines for clinical diagnosis of CAP have poor specificity we 
chose a stricter case definition based upon radiological findings (206). Cases with CAP were 
enrolled at two pediatric hospitals in Stockholm both at the emergency unit and at inpatient 
wards during three consecutive respiratory seasons.  
A total of 121 cases were included during the study period. Of these, 72% presented with 
fever, 72% were tachypnoeic, 59% had chest indrawings, 76% were admitted to inpatient wards 
and 2% were transferred to a pediatric intensive care unit. None died during the study period. 
Surprisingly as much as 81% of the cases tested positive for one or more virus. This is 
remarkable given that 95% of the cases received treatment with antibiotics for a suspected 
bacterial infection. Did all these patients really have a bacterial disease or were some of these 
children in fact suffering from a misclassified viral infection?  
 
 
Figure 9. Respiratory viruses in children <5 years with community-acquired pneumonia. PCR data of 
respiratory viruses detected in nasopharyngeal aspirates of cases with pneumonia (purple) and healthy 
controls (green). Data presented as proportion of positive patients. Abbreviations: RSV, respiratory 
syncytial virus. 
 
 
4.1.3.2 Case-Control Analyses 
To further assess the association between respiratory viruses and CAP, conditional logistic 
regression analysis was performed taking into account the viral detections among the controls. 
Indeed, certain viruses were commonly detected in controls, mainly RV, HBoV and HCoV 
once again underscoring the importance of proper controls in studies of respiratory infections 
in children (figure 9). However, RSV (OR=10.1, 95% CI: 4.8-21.2), hMPV (OR=6.5, 95% CI: 
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3.0-14.1) and influenza virus (OR=4.2, 95% CI: 1.2-14.5) were only sporadically detected in the 
controls and highly associated with CAP. A week association with CAP was also seen for HAdV 
(OR=2.1, 95% CI: 1.0-4.3) but the association was not significant when adjusting for potential 
confounders. RSV, influenza or hMPV were detected in 60% of all cases questioning whether all 
the children with allegedly bacterial CAP really had a bacterial disease.  
 
 
4.1.3.3 A Review of The Literature 
The high degree of virus detections in childhood CAP found in Paper III, is supported by a 
prospective US study by Jain et al on >2000 hospitalized children with radiological CAP (56). 
They reported that viral etiology was likely in as much as 66% of all cases (figure 3b) (56). They 
reported similar detection rates of RSV (28% in all subjects, 37% in children below 5 years 
versus 32% in our study), hMPV (13% in all subjects, 15% in children below 5 years vs 23% in 
our study) and influenza (7% in both studies). They also sampled >500 hospital-based controls 
where all viruses except for RV (detected in 17%) were infrequent findings (≤3%), but no 
formal case-control analysis was performed.  
 
Table 8. Viruses Associated with Pneumonia in Case-Control Studies using PCR 
Study Country 
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Fry/Dare et al, 
2007 (207–209) 
Thailand n/a	 n/a	 n/a	 x	 	 n/a	 n/a	 n/a	 	
Berkley et al,  
2010 (55) 
Kenya n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 x	 n/a	
Wolf et al,  
2010 (210) 
Israel n/a	 n/a	 n/a	 n/a	 n/a	 x	 n/a	 n/a	 n/a	
Mathisen et al,  
2010 (124) 
Nepal 	 x	 n/a	 n/a	 n/a	 x	 x	 x	 n/a	
Feikin et al,  
2013 (211)  
Kenya 	 x	 	 n/a	 n/a	 	 	 x	 	
Yoshida et al,  
2013 (149) 
Vietnam n/a	 x	 	 	 	 	 	 x	 	
Rhedin et al,  
2015 (212) 
Sweden 	 x	 (x)1	 	 	 x	 	 x	 	
Self et al,  
2015 (63) 
US 	 x	 	 	 x	 x	 x	 x	 	
Zar et al,  
2016 (59) 
South Africa 	 x	 x	 x	 	 	 x	 x	 	
Spichak et al,  
2016 (213) 
Russia 	 x	 x	 	 	 x	 	 x	 	
PERCH 
(preliminary) (214) Multi-center
1 	 x	 	 	 	 x	 x	 x	 	
“x” indicates a significant association with community-acquired pneumonia.  
1 Not significant in adjusted analysis. 2 PERCH study centers: Bangladesh, The Gambia, Mali, 
Kenya, South Africa, Thailand and Zambia. Abbreviations: n/a, not assessed 
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Several case-control studies assessing the role of viruses in CAP have recently been published 
(table 8). Yoshida et al compared viral findings in Vietnamese children with WHO clinical CAP 
and in community controls. They reported significant associations for influenza A (OR=8.3) 
and RSV (OR=21.91). Self et al, reported significant associations with radiologically confirmed 
CAP for RSV (adjusted OR=15.2), hMPV (aOR=10.4), PIV (aOR=2.3) and HCoV (aOR=3.2) 
from a prospective study on children with CAP and hospital-based asymptomatic controls in 
the US (63). Zar et al, reported, in line with our study, that RSV (OR=8.1) and Influenza 
(OR=4.1) were associated with WHO clinically defined CAP in a nested case-control study of 
284 South African children (59). In contrast to our study, they also found significant 
associations for HAdV (OR=2.2), HBoV (OR=2.3), PIV (OR=2.0) and cytomegalovirus 
(OR=1.6) but did not find a significant association with CAP for hMPV. One reason could have 
been the less specific definition of CAP that was used, which likely resulted in misclassification 
of children with bronchiolitis and wheezy bronchitis. Indeed, they reported that only 20 of 80 
performed chest radiographs showed infiltrates suggestive of CAP.  Spichak et al, presented data 
from a case-control study on 56 Russian children with radiologically confirmed CAP (213). 
Despite the limited study size, they could report significant associations for RSV (OR= 7.7), 
hMPV (OR=21.1), influenza (OR=16.4) and HAdV (OR=15.5). Finally, preliminary data from 
the PERCH study show significant associations for influenza, RSV, hMPV and PIV (214).  
In view of these studies, the significant associations with CAP for influenza, RSV and hMPV 
seem to be uncontroversial (table 8). It is surprising that PIV was not associated with CAP in 
Paper III. Our study period covered three consecutive seasons and variations in epidemiology 
over time, which is common for many respiratory viruses, should have been captured. 
Nevertheless, PIVs seem to be rather infrequent findings in CAP and our PCR panel did not 
include PIV4. Hence, we cannot exclude type-2 error as an explanation for the absence of a 
detected association. It could also be a result of PCR escape due to antigenic drift since PIV is an 
RNA virus with a high mutation rate. Indeed PCR escape was reported to be the reason behind 
a declining incidence of Chlamydia trachomatis in Stockholm, Sweden and has also been 
reported for influenza A (215,216). Whole genome sequencing of selected samples from the 
study are planned, which will potentially solve this issue.  
 There is disagreement between the CAP studies regarding the role of HAdV (table 8). In 
Paper III, significant association with CAP was seen for HAdV in the crude estimates, but this 
association disappeared in the multivariate analyses. Again, type-2 error is a likely possibility as 
the virus has previously been reported to be associated with CAP (59,213). Nevertheless, it is 
questionable whether PCR-positivity alone should be considered sufficient for diagnosis given 
the extensive detection in asymptomatic children (59). Interestingly, none of the case-control 
studies have supported a role of picornaviruses in CAP, contrasting several previous case 
reports (90). Although detection of EV or RV with current PCRs seems to be of limited 
significance in childhood CAP, certain strains such as EV-D68 have been associated with severe 
respiratory disease and future PCRs should perhaps focus on selected serotypes. With the 
exception of Iwane et al, none of the studies above report data on serotypes, which hampers 
interpretation on the role of distinct picornavirus serotypes in CAP.  
To conclude, influenza, RSV, hMPV and PIV have been associated with CAP in several 
studies whereas the role of HAdV, HBoV and HCoV is less clear. There is currently no evidence 
from case-control studies for a role of RV or EV in CAP. 
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4.1.3.4 Association or Causal Relationship? 
Similar to the discussion regarding the findings from Paper II, potential sources of bias such as 
confounding need to be considered to correctly interpret the significant associations between 
respiratory viruses and CAP in Paper III. Again, bacterial infection is the most important 
confounder and this was something we could not adequately control for given that the bacterial 
diagnostic testing was incomplete. Induced sputum samples, blood cultures and paired serology 
are additional samples that could have added robustness to the results but were not feasible to 
obtain due to logistic and financial reasons. In the routine microbiological workup that was 
performed by the attending physicians, a bacterial cause could be confirmed in a very limited 
number of cases. Only one out of 29 (3%) performed blood cultures were positive (growing S. 
pneumoniae serotype 38), 2/26 (8%) patients tested positive for M. pneumoniae by PCR and 
5/121 (4%) of the children had evidence of pleural effusion on the chest radiographs, which is 
also indicative of bacterial etiology. There is clearly a need for improved microbiological 
diagnostic tests to distinguish between bacterial and viral CAP. 
Another important potential confounder is socio-economic status (SES) as low SES could be 
considered to be associated both with a higher exposure to respiratory viruses as well as to an 
increased risk of CAP (outcome). Despite our efforts to sample controls representative of the 
cases at 33 different child health centers, we observed significant socio-demographic differences 
between the groups. For instance, smoking was more common among the parents of the cases 
and they also had a significantly lower educational level as compared to the parents of the 
controls. Average purchase power based on the residential areas of all study subjects was 
obtained to compare the study subjects with the general population (217). The cases lived to a 
larger extent in areas with a lower average purchase power index as compared to the controls 
(index 1.16 vs 0.75, p<0.001). Moreover, the average purchase power of the control’s residential 
areas was higher as compared to the general population in Stockholm indicating that we 
selected a “too wealthy” control population. This could partly be explained by a lower 
participation rate (estimated to 50%) among the controls than among the cases (estimated to 
90%) as parents with low socioeconomic status usually are less likely to participate in research 
studies. We tried to adjust for the differences in a multivariate logistic regression analysis by 
including smoking and parental education level as predictors, which did not significantly alter 
the results. Nevertheless, as we did not have individual data on purchase power we could not 
adequately control for SES and thus residual or uncontrolled confounding by SES possibly 
overestimating the observed associations is a limitation of the study. 
To conclude, Paper III adds further evidence that influenza, RSV and hMPV are causally 
associated with CAP. However, owing to the limitations above, we cannot tell whether they 
were the sole causes of disease or merely paved the way for undiagnosed secondary bacterial 
infections. 
 
 
4.1.3.5 Estimation of CAP Etiology  
Is it possible to give an estimate of the proportion of bacterial, viral and mixed bacterial-viral 
infections in Paper III? In the introduction of this thesis, two different CAP etiology estimates 
by Scott et al and Jain et al were presented (figure 3). Jain et al considered PCR-positivity for 
any respiratory virus indicative of viral CAP in the absence of bacterial diagnosis (defined as 
bacteria detected in blood or pleural fluid) (56). This definition can be criticized for lack of 
specificity and likely overestimated the proportion of viral CAP. Based on the current literature, 
it would seem more reasonable to limit the definition of viral CAP to detection of influenza, 
RSV, hMPV and PIV (table 8). An interesting study by Virkki et al reported that CRP cut-offs of 
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>80g/l in children <2 years and >120g/l in children >2 years were reasonably specific for 
bacterial etiology (218). In contrast, CRP <20 g/l was indicative of viral etiology. Could these 
cut-offs perhaps aid in the definition of the less obvious bacterial or viral cases? Figure 10 shows 
the estimated etiology in the cases from Paper III using a definition based of laboratory 
findings and CRP cut-offs as described by Virkki et al. In this estimate, respiratory viruses are 
the most common causes (45%) followed by mixed viral-bacterial (29%) and bacterial etiology 
(14%).  
 
 
 
 
Figure 10. Estimation of CAP Etiology in Paper III.  
Etiology of n=121 children with radiographic community-acquired pneumonia based on microbiological 
findings and CRP as follows: Viral CAP: PCR positive for influenza, RSV, hMPV, PIV, HAdV or PCR 
positive for other respiratory viruses if CRP <20. Bacterial CAP: Positive blood/pleura culture or lobar 
consolidation/large dense infiltrate on chest x-ray or CRP >80g/l in children <2 years/ >120g/l in children 
>2 years. Mixed viral-bacterial infection: fulfilling definitions for both viral and bacterial CAP. Atypical 
bacteria: Not fulfilling any above AND positive M. pneumoniae. 
 
 
4.1.4 Febrile Neutropenia (Paper IV) 
4.1.4.1 Rationale of the Study 
Respiratory viral infections are common in immunocompetent children; it is thus likely that 
they also play a role in febrile episodes in immunosuppressed children. Previous studies have 
indicated that respiratory viruses are commonly detected in children with FN, but none of these 
have compared the findings to a reference group, which is important considering the high grade 
of asymptomatic detections of viruses in children (13). In Paper IV, the presence of respiratory 
viruses was investigated during episodes of FN in children under treatment for malignancies. A 
longitudinal study design with repeated sampling was used, as an alternative to the case-control 
design. With this strategy, the cases served as their own individual controls.  
 
 
4.1.4.2 Assessing the Role of Viruses 
At least one respiratory virus was identified in 39 (45%) of the 87 episodes. Previous case series 
have reported a detection rate between 44-57% (72,201,219–221) (table 9). RV and HCoV were 
the most common microbiological findings detected in 24% and 8% respectively (figure 11). A 
relatively low number of presumably more pathogenic viruses was detected, such as RSV, 
hMPV, influenza and a parainfluenza. This is in agreement with the fact that the majority of 
cases had mild respiratory symptoms.  
  48 
Table 9. Viruses Detected by PCR in Children with Febrile Neutropenia 
Study Country 
Percentage of 
positives 
Most common findings 
Koskenvuo et al, 2008 (201) Finland 61/138 (44%)1 Rhinovirus, RSV 
Lindblom et al, 2010 (200) Sweden 41/90 (46%) Rhinovirus, adenovirus 
Torres et al, 2012 (219) Chile 190/331 (57%) RSV, rhinovirus, parainfluenza virus 
Suryadevara et al, 2012 (220) US 26/50 (52%)2 Rhinovirus, influenza 
Söderman et al, 2016 (142) Sweden 39/87 (45%) Rhinovirus, coronavirus 
Santolaya et al, 2017 (221) Chile 441/951 (46%) Rhinovirus, RSV, parainfluenza virus 
1 HCoV-HKU1/NL63 not assessed. RSV, PIV, HAdV, influenza detected by immunofluorescence assay. 
2 HBoV not assessed. Abbreviations; PCR, real-time polymerase chain reaction; RSV, respiratory syncytial 
virus. 
 
 
A follow-up sample was obtained for 32 of the virus-positive episodes to give a better picture of 
whether the detected virus was the result of asymptomatic shedding or indicated symptomatic 
infection. In 25 episodes (78%) the virus was cleared at follow-up (median time of 28 days). 
Sequencing of repeatedly positive RV samples revealed different serotypes in two cases. Hence 
the true clearance was 27/32 (84%). Shedding time of respiratory viruses is of particular interest 
in immunosuppressed children for the decision regarding isolation and cohorting as viral 
respiratory infections can be lethal in this group (130). The study was not designed to assess 
shedding time of specific viruses accurately, yet only a minority of viruses persisted >4 weeks. 
 
 
 
Figure 11. Respiratory viruses in children <5 years with febrile neutropenia. PCR data of respiratory 
viruses detected in immunosuppressed children during episodes of febrile neutropenia (indigo) and at 
follow-up (green). Data presented as proportions. Abbreviations: RSV, respiratory syncytial virus. 
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Despite the longitudinal design, the lack of a proper control group complicates the 
interpretation of the viral findings. Indeed, as discussed above the two most frequent findings, 
HCoV and RV, are reported to be common in asymptomatic children (13). Asymptomatic 
detection of respiratory viruses has not been properly assessed in immunosuppressed children. 
It is plausible that HCoV and RV are more pathogenic in the absence of a proper antiviral 
immune response. Studies of asymptomatic immunosuppressed children are needed to further 
evaluate the significance of PCR-positivity for certain respiratory viruses in this group. 
How, can the findings from Paper IV be interpreted? In contrast to Paper I-III, where the 
bacterial testing was rather incomplete, an extensive microbiological workup including repeated 
blood cultures was performed in the majority of study subjects in Paper IV, as this is part of the 
routine management of children with FN. Despite this, only eight (9%) episodes of septicemia 
were recorded (of these, a respiratory virus was also detected in three episodes). All of these 
received treatments for an underlying hematological malignancy. It is known that stem cell 
recipients are at high risk for septicemia, which needs to be considered in the assessment of 
these children (199).  
In 43 (49%) episodes, no pathogen was identified. Pediatric blood cultures have limited 
sensitivity; hence some of the culture-negative patients might still have suffered from a bacterial 
infection. This complicates implementation of the findings into clinical practice. Further, given 
that septicemia is such a severe disease and that antibiotic treatment historically has saved many 
lives in this group, implementing changes in the management of children with FN is a delicate 
task. It is unrealistic to believe that rapid viral diagnostics will have a significant impact on the 
administration of empirical antibiotic treatment in children with FN. Nevertheless, an 
interesting randomized controlled trial from Chile assessing treatment strategies in children 
with FN was recently published by Santolaya et al (221). The study evaluated safety and efficacy 
of withholding antibiotic treatment after 48 hours in children with negative blood cultures that 
tested positive for respiratory viruses. They reported low and similar complication rates in both 
groups and reinstallment of antibiotics was necessary for only 4/84 (5%) of the children in the 
antibiotic withholding group. The South American study shows that it is possible to implement 
an algorithm for discontinuation of antibiotics in children with FN, based on findings of 
respiratory viruses. This approach has great potential to reduce the antibiotic pressure in these 
patients. 
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4.2 VIRAL DIAGNOSTICS FROM A CLINICAL PERSPECTIVE 
4.2.1 Significance of PCR-Positivity 
The clinical significance of PCR-positivity of viruses in upper respiratory specimens has been 
questioned due to frequent detection of several viruses in asymptomatic children (2). PCR is not 
a functional assay and positivity indicates the presence of short virus-associated motifs of 
nucleic acid rather than the presence of viable infective virions. Methodological advancements, 
as well as good laboratory practice (usage of separate rooms, well-ventilated hoods, internal 
positive and negative controls etc.), have decreased the number of false positive test results (2). 
Moreover, given the unstable nature of the RNA molecule, it is unlikely that viral RNA 
fragments would persist a longer period in the respiratory tract without replicating. Indeed, 
degradation of RNA viruses associated with storage and handling of respiratory samples is a big 
concern when conducting studies on respiratory viruses. Further, as viruses are intracellular 
particles and replication requires infection of human cells, some claim that PCR-positivity in 
asymptomatic children always should be considered indicative of active infection, albeit 
sometimes subclinical (12). Regarding DNA viruses, this is not as clear given that these viruses, 
in general, are much more stable. Persistence of HAdV and HBoV in the respiratory tract have 
been reported (222). From a clinical utility perspective, the most important thing to know about 
the PCR result is whether it detects the causative agent or not, no matter if the potentially false 
positive result was due to mucosal contamination or indicated a true albeit subclinical infection. 
In Paper II, respiratory viruses were detected in more than a third of the asymptomatic 
controls. However, no follow-up of the study subjects was conducted and hence we could not 
say whether the controls developed respiratory symptoms after enrolment. It is likely that some 
of the virus-positive controls were sampled in the early phase of an uprising infection.  
 
 
4.2.1.1 Asymptomatic Virus Detections by PCR 
To further evaluate asymptomatic detection of viruses in the respiratory tract of children a 
literature review was performed and data from n=25 studies reporting PCR data on 
asymptomatic children were compiled (figure 12). In line with the findings from Paper II-III, 
detection of hMPV, RSV, influenza, EV and PIV was rare in asymptomatic children detected in 
0.6%, 1.3%, 1.5% and 1.8% and 2.3% respectively (figure 12). Interestingly, with the exception 
for EV, all these viruses are enveloped RNA-negative viruses that are known to be more 
unstable and sensitive to drying and detergents as compared to non-enveloped ones (73). For 
EV, the interpretation of the meta-analysis is hampered by the limited power, given that EVs 
are infrequently detected also in symptomatic children with respiratory disease. Further, most 
PCRs are limited at distinguishing between RV and EV.  
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Figure 12. Detection of respiratory viruses in asymptomatic children. Compiled PCR data from earlier 
studies (n=27) on upper respiratory specimens from asymptomatic children (<18 years). Data 
presentedas the proportion of positives. References: (27,80,204,208,209,223–245). Abbreviations: RSV, 
respiratory syncytial virus.  
 
HAdV (7.5%), HBoV (13.4%), HCoV (6.7%) and RV (27.4%) were frequently detected in 
asymptomatic children thus obscuring the clinical significance of a finding (figure 10). This is in 
agreement with the results from Paper II-III. Regarding RV, HAdV and HCoV, differential 
pathogenicity between serotypes could be one explanation for the high asymptomatic detection 
rate. In Paper IV, all RV were sequenced to determine serotype. Indeed, only RV-A and RV-C, 
were found in the cases, which have been reported to be more pathogenic as compared to RV-B 
(140,209). Due to financial reason, RVs were not sequenced in Paper II-III but it would indeed 
be interesting to know whether RV-B was more common in the controls as a result of low-
virulent, asymptomatic infection. In terms of HAdV, it was recently shown that HAdV-C 
accounts for the majority of incidental HAdV detection in culture negative children (246). Since 
we did not have data on HAdV serotypes we cannot exclude a significant association between 
HAdV and CAP for individual serotypes. Exclusion of HAdV-C from the conventional PCR 
panel could be one possible measure to improve the clinical significance of PCR-positivity for 
that virus. Regarding HCoV, the limited number of observations positive for HCoV in the 
meta-analysis did not allow for individual assessments of specific serotypes. Interestingly, 
HCoV-OC43 was only detected in cases in Paper II (n=4). HBoV, is a virus commonly detected 
together with other respiratory viruses and its pathogenicity has been diligently debated since its 
discovery (86). Although it is established that the virus is a real human pathogen, it seems to 
cause persistent infection in some individuals. This is similar to other viruses in the 
Parvoviridae family and complicates interpretation of PCR-positivity (88,247). A limitation in 
the majority of the studies included in the meta-analysis was the lack of follow-up of symptoms 
to exclude children who were in the early phase of an infection.  
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4.2.1.2 Viral Shedding Time 
Byington et al performed a longitudinal study with collection of weekly nasal swabs, as well as 
symptom diaries, from US children (11). They reported that all viruses except HBoV and RV 
were cleared from the respiratory tract within four weeks from the start of the infection. A 
limitation to the study was that RV specimens were not genetically sequenced. In another 
longitudinal study by Loeffelholz et al, the RV-positive specimens were genotyped, which 
showed that persistence of RV >4 weeks was rare (<5%) (248). 
 
 
4.2.1.3 Significance of Viral Load  
Jansen et al reported that RV-positive children with RTI, had higher viral loads as compared to 
RV-positive asymptomatic children in a prospective case-control study and speculated whether 
a cut-off could aid in the interpretation of PCR (80). As discussed in the methods section, the 
PCR method used in Paper I-IV was not designed to assess viral load accurately. Nevertheless, 
the CT-value, i.e. the number of cycles needed to amplify the target RNA/DNA to a detectable 
level, is inversely related to the input quantity and can thus be considered a rough estimate of 
the viral load. CT-values in virus-positive cases and controls from Paper II-III were assessed 
(figure 13). The median CT-values of detected HAdV, hMPV, PIV, RSV and RV were 
significantly higher in controls as compared to cases indicating a lower viral load. Although the 
data points largely overlap, it suggests that high CT-values have limited clinical significance. 
 
 
 
 
 
Figure 13. CT-values of Virus-Positive Children. Scatter plot presenting individual CT-values of virus-
positive cases with respiratory tract infection (pink) and controls (green). Horizontal lines representing 
medians. Abbreviations: CT, cycle-threshold; HAdV, adenovirus; HBoV, bocavirus; HCoV, coronavirus; 
EV, enterovirus; Flu, influenza virus; hMPV, metapneumovirus; PCR, real-time polymerase chain 
reaction; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RV, rhinovirus. 
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4.2.2 Viral Co-Infections and Disease Severity 
The role of viral co-infections in terms of disease severity is debated (182). As the sensitivity and 
microbiologic spectrum of our diagnostic tests increase, an increasing number of potential 
pathogens will be detected (2). In Paper I, viral co-infections were investigated over time in 
children with ILI. The study period ranged from July to December 2009. The number of co-
infections increased over time, both in all PCR positive patients and in the subgroup of 
influenza positive children, to peak in December (figure 14). This is in line with a study by 
Grady et al who reported that low age, daycare attendance and Winter season was 
independently associated with viral co-infection (249).   
 
 
Figure 14. Viral Co-Infections over Time. Number of cases with viral co-infections in hospitalized 
children with influenza-like illness during 2009.  
 
 
The increased probability of co-infections during Winter is likely explained by two different 
mechanisms. First, RTIs, in general, are relatively uncommon during the summer months but 
increase in frequency during fall, owing to the start of schools and daycare facilities as well as to 
the climate getting dryer (103). As several different viruses are circulating at the same time, 
children infected with one particular virus will remain at risk for acquiring new infections of 
other viruses during their symptomatic phase, i.e. will result in an increased risk of co-
infections. Second, as discussed above, many respiratory viruses are shed for a period after 
recovery. An increase in the acquisition rate of new infections will hence result in an 
accumulation of viral remnants from previous infections i.e. increase the number of false 
positive detections. Although it is sometimes a delicate matter to distinguish between true 
infective agents and contamination/colonization, an increasing number of studies suggest that 
many RTIs in children are caused by multiple pathogens (59,213).  
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4.2.2.1 Co-Infections in Children with Influenza 
In Paper I, the association between co-infection and disease severity was specifically assessed in 
children with H1N1, as contrasting results previously had been reported (250,251). We could 
not detect any significant differences between children with H1N1 single infection and H1N1 
viral co-infection in terms of disease severity (ICU treatment, complications, length of stay). 
This could be due to type-2 error since the power of the study was limited but it is also likely 
that co-infections with different viruses have a varying effect on disease severity. In Sweden, the 
H1N1 pandemic terminated before the peak of the seasonal RSV epidemic and we only detected 
low numbers of RSV during the study period. In contrast, high mortality was reported in Brazil 
where the two epidemics largely overlapped (250). Indeed, the high morbidity associated with 
influenza/RSV co-infection was recently shown in a large US cohort study by Lim et al (252).  
Viral co-infections were also assessed in Paper II, and multiple viruses were detected in 
42/229 (20.1%) cases. Viral co-infection, in general, was associated with discharge diagnoses of 
CAP (p<0.01) and bronchiolitis (p=0.02) as well as with signs of severe disease including 
decreased oxyhemoglobin saturation (p=0.04), tachypnea (p<0.01) tachycardia (p=0.05) and 
fever (p=0.05). The most common virus combinations were HBoV/HRV, HAdV/HRV, and 
HBoV/RSV, but the study size did not allow any further assessment of specific virus-virus pairs 
associated with disease severity. To conclude, there is little evidence of a general increase in 
disease severity by viral co-infection, however certain combinations, such as influenza/RSV, 
have been associated with high morbidity. 
 
 
4.2.2.2 Viral Co-Infections in Asymptomatic Children 
The study design used in Paper II and Paper III allowed for assessment of co-infections also in 
asymptomatic children. In Paper II viral co-infections were detected in 11/229 (5.3%) 
asymptomatic control children. Remarkably, in Paper III, two previously healthy control 
children without reported respiratory symptoms had five different viruses detected 
(hMPV/PIV3/RV/HBoV/HCoV-OC43 and hMPV/RV/HBoV/ HAdV/HCoV-HKU1 
respectively). Both of these children were also positive for S. pneumoniae in nasopharyngeal 
bacterial cultures (serotype 35F). No follow-up was performed on the study subjects and hence, 
we cannot tell whether this was a consequence of an impaired antiviral defense or if it occurred 
by chance. It is possible that respiratory co-infections are overrepresented in children with 
humoral immune defects as a result of an impaired virus clearance. Indeed, many primary 
immune defects usually become manifest in this age. However, this was not supported by Paper 
IV, given that the proportion of viral co-infections (7%), as well as the viral shedding time in the 
immunosuppressed children, seemed to be similar to what has been reported for 
immunocompetent children.  
 
 
 
4.2.3 Interference between Respiratory Pathogens 
4.2.3.1 Interference between Rhinovirus and Influenza A(pdm09) 
An improved understanding of interference between different virus outbreaks is essential for 
disease prevention, not least regarding influenza surveillance. The rapid decline in H1N1 cases 
seen in December 2009 is interesting since the seasonal influenza epidemics, in general, peak 
later during the winter season. In contrast, RV is usually detected throughout the year with a 
peak during fall/early winter. Could the high levels of circulating RV explain the slow spread 
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and rapid decline of H1N1? Naturally, several possible explanations are confounding this 
observation but let us examine the data from Paper I. Figure 15 shows the number of cases over 
time for the two viruses. It is clear that both RV and H1N1 circulated during the whole study 
period and in fact, the two curves seem to follow each other and are both peaking in November. 
Moreover, five (6% of all H1N1 positive children) patients had co-infection with RV and H1N1. 
This would rather speak against the suggested negative interaction by RV on the H1N1 
pandemic. 
 
 
 
 
Figure 15. Detection of H1N1 and rhinovirus over time. Number of positive cases in hospitalized 
children with influenza-like illness during 2009. Abbreviations: H1N1, influenza A H1N1(pdm09); RV, 
rhinovirus. 
 
 
The study relied solely on microbiological data from hospitalized cases with ILI and no data 
were available on controls. This made it impossible to estimate the virus circulating in the 
society where the potential interference would have taken place and advanced interaction 
analyses could not be performed. Nevertheless, other studies have supported the theory of 
interference between respiratory pathogens. Cowling et al reported that children receiving 
seasonal influenza vaccine had an increased risk for infection from non-influenza viruses in a 
randomized controlled trial (253). Moreover, interference between flaviviruses has been 
reported. Antibodies against dengue virus seem to predispose for zika virus infection by 
antibody-dependent enhancement (254). In Paper III, HCoV and HBoV were negatively 
associated with CAP. Could this be suggestive of a protective effect of infection with these 
viruses? Significant negative associations with CAP for HCoV was also reported in the 
preliminary results from the large PERCH study (ref RSV16 O’Brien). One explanation to the 
findings could be that the antiviral immune response elicited in the cases with presumably viral 
CAP protected against co-infection with HCoV.  
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4.2.3.2 Interference between Viruses and Bacteria 
Regardring viral-bacterial interaction, there are solid data on the existence of interference 
between S. pneumoniae and respiratory viruses from large-scale observational vaccine studies 
(255,256). Weinberger et al reported a significant decline in hospitalizations for RSV infection in 
the US following the introduction of PCV in the national child immunization program (257). 
Madhi et al reported a decreased number of hospitalized children with viral CAP in South 
Africa after the introduction of PCV (256). H. influenzae is another pathogen commonly 
detected together with respiratory viruses, but the importance of such viral-bacterial co-
infections needs to be further assessed (249). Co-colonization of S. pneumoniae and H. 
influenzae has been reported in several cross-sectional studies and there is increasing evidence 
of positive interaction between the two bacteria (160). In contrast, colonization of S. 
pneumoniae seem to decrease the probability for carriage of S. aureus, which has led to concerns 
about potential unwanted side effects from the PCV immunization (160).  
 
 
4.2.4 Clinical Presentation of Respiratory Viruses 
Clinicians commonly use symptoms and signs identified in the physical examination in the 
assessment of children with respiratory infection. Nevertheless, disease presentation of specific 
respiratory viruses is not entirely understood. In Paper I, we found a plethora of different 
viruses in the 502 children with influenza-like illness during the H1N1 pandemic. One reason 
was likely a liberal admission policy due to fear of severe H1N1 infection leading to 
hospitalization of a heterogeneous group of patients, yet the study underscores the overlap in 
symptoms of different viral respiratory infections as all cases were clinically suspected of having 
influenza. A recent systematic review reported that there is a lack of evidence supporting agent-
specific symptom patterns for most respiratory viruses (258). The exception was RSV where 
significant associations with indrawings, wheezing and crepitations were seen for the pathogen 
in the meta-analysis (258).  
 
 
Table 10 – Symptoms Associated with Detection of Respiratory Viruses  
Virus Associated symptom/characteristic 
Adenovirus hypoxia (13) 
Bocavirus tachypnea, tachycardia, cough (13) 
Enterovirus fever  (30) 
Metapneumovirus tachypnea, hypoxia, tachycardia, fever (13) 
Parainfluenza virus viral croup diagnosis (13) 
Respiratory syncytial virus 
tachypnea, wheezing (13) 
productive cough, fever, age <2 years (30) 
Rhinovirus 
coryza (13)  
blocked nose (30) 
absence of fever (13,30) 
Data acquired from Rhedin et al and Thornton et al (13,30).  
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In Paper II, clinical symptoms and discharge diagnoses associated with detection of specific 
viruses were investigated in the cases with ARI. We were able to reproduce the reported 
association between PIV and viral croup (121). Moreover, RV was associated with coryza and 
absence of fever, i.e. suggestive of mild URTI. In contrast, hMPV and HBoV were associated 
with signs of severe LRTI. 
There are some limitations to the analyses in Paper II mentioned above. First, type-I-error is 
a possibility given the numerous tests performed. Indeed, when performing Holm’s correction 
for multiple testing, none of the reported associations remain significant (data not shown). 
Second, the presence of viral co-infections complicated the interpretation. For instance, the 
majority of children with HBoV were co-infected with other respiratory viruses and there was a 
tendency that HBoV single infected children had a less severe disease as compared to HBoV co-
infected children. This suggests that some of the morbidity could partly be attributed to the co-
infecting viruses. A large-scale British prospective study, that assessed symptoms associated 
with respiratory agents in children in the primary care, was recently published by Thornton et al 
(30). In line with the findings from Paper II, they reported significant associations with non-
febrile illness and blocked nose for RV whereas RSV was associated with signs of severe disease 
(table 10).  
To conclude, there is currently limited evidence for agent-specific symptoms for viruses 
other than RSV and the clinical presentation of respiratory viruses largely overlap. 
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5 CONCLUDING REMARKS 
 
• Several different viruses are detected in children with influenza-like illness and viral co-
infections is common in influenza-positive children, which needs to be accounted for 
when attributing morbidity to influenza. 
 
• The majority of episodes of acute respiratory illness in children can be attributed to 
rhinovirus. Other viruses significantly associated with the disease are bocavirus, 
parainfluenza viruses, respiratory syncytial virus and metapneumovirus.  
 
• Respiratory syncytial virus, metapneumovirus and influenza virus are highly 
associated with radiological community-acquired pneumonia in children and viral 
pneumonia is likely an underdiagnosed disease. 
 
• Respiratory viruses are commonly detected in immunosuppressed children during 
episodes of febrile neutropenia and prolonged viral shedding is infrequently seen 
suggesting a causal relationship. 
 
• Asymptomatic detection of respiratory viruses in upper respiratory specimens is not 
uncommon in children. Detection of adenovirus, bocavirus, coronavirus, enterovirus 
and rhinovirus by PCR needs to be interpreted with caution in children with 
respiratory tract infection. 
 
• Viral co-infection, in general, is not associated with increased disease severity, but 
certain virus combinations might be, such as influenza/respiratory syncytial virus. 
 
• Complex interactions seem to occur between several respiratory pathogens but this 
needs to be investigated further in large population based studies or in experimental 
designs. 
 
• Some respiratory viruses are associated with specific symptoms such as respiratory 
syncytial virus with wheezing, but the disease presentation of respiratory viruses largely 
overlap. 
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6 FUTURE PROSPECTS 
6.1 PREVENTION AND TREATMENT 
More than eighty years have passed since the discovery of the first virus, yet remarkably few 
antivirals are approved for treatment of respiratory infections. In contrast to the area of 
bacteriology, where the discovery of penicillin completely changed the whole field of medicine, 
there are still no “wonder drugs” with broad-spectrum antiviral activity. New vaccines and 
antivirals targeting respiratory viruses have great potential to fight childhood mortality and 
morbidity. The need for antivirals is biggest in the context of immunosuppressed children, for 
instance, the mortality of viral CAP in stem-cell recipients is 25-45% (130). 
RSV is an excellent vaccine candidate as the virus is estimated to cause 66 000-199 000 
deaths annually (259). Implementing an immunization program usually increases the average 
age of disease acquisition in the given population. No vaccines have a 100% efficacy and even if 
they result in a decreased amount of circulating virus, they will usually not make the virus 
disappear completely. This means that the exposure among non-immunized will decrease 
whereas the average time to disease increases. This effect can sometimes be a problem, as 
certain infectious diseases have a more severe clinical course if caught in adulthood as 
compared to childhood. If the vaccine efficacy is not good enough, then implementing a vaccine 
against such a disease could do more harm than good. Nevertheless, regarding RSV, this age 
effect would only prove beneficial given that infants are the ones that are at highest risk for 
severe disease. Developing an RSV vaccine is currently prioritized by many fundraising 
organization including the WHO and the Bill & Melinda Gates Foundation. Unfortunately, 
eliciting a long-lasting immune response to RSV without side-effects has proven difficult. There 
are currently more than 60 vaccine candidates ranging from preclinical studies to late Phase III 
studies, yet a well-functioning vaccine is likely many years ahead (133). Vaccination of infants is 
particularly challenging owing to their immature adaptive immune system. An alternative 
strategy currently receiving much attention, is maternal immunization, i.e. vaccination of 
mothers during pregnancy. As antibodies are transfused to the baby continuously during 
pregnancy, vaccination of mothers prior to delivery would provide protection to the child 
during the first critical months where they are at highest risk for severe disease (260). 
Another paramyxovirus that only recently has received increased attention is hMPV. The 
virus attributes to substantial morbidity in children not least in immunosuppressed individuals 
(115,261). In Paper III, 23% of Swedish children hospitalized with CAP tested positive for 
hMPV. Such epidemiological studies are necessary to raise the awareness among scientist and 
industry stakeholders that the virus should be a highly prioritized target for future antivirals. 
Vaccination could be another potential future intervention, not least in certain high-risk 
groups, but so far no vaccine projects have reached Phase I (262). Finally, for PIV a vaccine 
seems excessive, but given that the virus is associated with severe disease in immunosuppressed 
children, new antiviral treatments would certainly have a major role in this setting (130). 
There are some other viruses outside the paramyxovirus family who are worth discussing. 
HAdV is virus indeed capable of causing severe disease and a safe vaccine is already available, 
however, currently mainly used in US military recruits. Vaccination of certain high-risk groups 
in the civilian population might be considered in the future.  
Influenza virus attributes to significant morbidity and mortality globally and is sometimes 
the sole cause of death in previously healthy Swedish children (100). Seasonal vaccines are 
developed annually but currently only recommended to high-risk populations in Sweden. These 
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vaccines are both safe and effective and used in a broader population in many other countries. 
For instance, in the US all children are recommended a flu shot. It is likely that providing 
seasonal influenza vaccination to all Swedish children would prove cost-effective and decrease 
both mortality and morbidity in the general child population. Influenza is also the only virus 
where an active antiviral drug is available. The use of oseltamivir (Tamiflu®) in children, 
however, is very limited in Sweden. Likely due to limited diagnostics, but also to some extent 
due to lack of national guidelines (263,264). Given the extensive morbidity attributed to 
influenza and the high safety of current influenza treatment/vaccines, an increased use of 
oseltamivir, as well as nationwide immunization with seasonal influenza vaccines, would likely 
prove beneficial for the general child population. 
Regarding bacterial vaccines, the PCV has reduced the disease burden of S. pneumoniae 
significantly. Moreover, bacterial vaccines have the potential to specifically target clones highly 
resistant to antibiotics, which will likely play an even more important role in the future. The 
down-side of protein conjugate vaccines, however, is that they tend to lead to the replacement 
of non-vaccine clones and hence do not impact the colonization rate (9). In contrast, 
pneumococcal whole-cell vaccines have the potential to target all serotypes and hence impact 
colonization. An attractive whole-cell vaccine candidate has recently advanced to Phase II (265). 
Childhood obesity is an increasing global problem that was recently reported to be an 
independent risk factor for severe influenza infection (266). It is also known that several 
nutritional deficiencies have an adverse effect on the immune system and prolonged Vitamin D 
supplementation in children has shown promise in preventing RTIs (266,267). Interestingly, a 
pathogen-specific effect related to nutritional deficiencies was recently observed in selenium-
deficient mice. A benign strain of coxsackievirus had an increased mutation rate when 
inoculated in selenium-deficient mice, which resulted in increased pathogenicity also to non-
deficient mice (268). Indeed, fighting poverty remains an important task for improving the 
global child health.  
Finally, a big issue in pediatrics is the lack of approved indications and data on optimal 
dosage for existing drugs. Since most Phase III trials are performed on adults, predominantly 
males, several existing treatments are currently used off-label in children. This is a problem as 
children have a different metabolism and usually require substantially higher drug 
concentrations as compared to adults. For example, case reports of dental staining as an adverse 
effect of tetracycline treatment during pregnancy have for long limited the use of doxycycline in 
children ≤8 years [169]. This has favored the use of antibiotics with broader antimicrobial 
spectrum such as parenteral cephalosporins. Recently, these recommendations have been 
debated and there seems to be a lack of evidence that doxycycline increases the risk of dental 
staining, as opposed to older tetracyclines that had a much higher affinity for calcium (269). To 
limit the unregulated use, optimize dosing and evaluate historical dogmas, there is a need for 
clinical trials assessing the effect of existing antimicrobial drugs in a pediatric population, 
particularly in infants and neonates. 
 
 
 
6.2 DIAGNOSTICS 
The clinical WHO guidelines for diagnosing CAP need to be revised as they lack specificity and 
result in extensive misclassification of non-bacterial diseases as CAP (270). Point-of-care lung 
ultrasound could be one readily available tool to increase specificity without causing additional 
discomfort for the child and is increasingly used in South America (271). There is also a need 
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for new diagnostic tests that more accurately distinguish between viral and bacterial disease. 
Liquid chromatography tandem mass-spectrometry is a powerful tool to assess the complete 
proteome in diagnostic specimens and have been used to identify new biomarkers for 
respiratory infections (272,273) . Viral biomarkers such as myxovirus resistance protein A 
(MxA) and TNF-related apoptosis-inducing ligand (TRAIL) might be a valuable complement 
to current inflammatory biomarkers that are mostly focused on bacterial infections (274,275). 
Given the complexity of the immune system, it is likely that a panel of biomarkers will be 
needed to distinguish between viral and bacterial infections accurately. Powerful techniques for 
this is already available such as liquid chromatography tandem mass-spectrometry and 
transcriptional profiling techniques (272,276). Such transcriptomic and proteomic approaches 
will likely be used more frequently in the future in combination with NGS screening for 
microbes. Not least will it be useful in the intensive care unit setting. However, to really impact 
the management or RTIs and decrease the overuse of antibiotics, cheap, rapid tests with a short 
turnaround time are needed. Recombinase polymerase amplification (RPA) is a nucleic acid 
amplification method that is almost as sensitive as PCR but does not require thermal cycling. 
An RPA-based point-of-care test could combine the advantage of a high sensitivity with a short 
turn-around time (277). As the test reaction can be carried out at room temperature, it is a 
particularly appealing method for resource-limited settings where the need for new diagnostic 
tests is high (278).  
From a public health perspective, it is also important to implement existing guidelines. An 
Indian study reported that only 13% of children with CAP were given guideline concordant 
treatment, underscoring the need for continuous education of health care workers (279). 
Further, the unregulated over the counter selling of antibiotics that exist in many countries 
needs to be dealt with. It is important to keep in mind, though, that lack of access to antibiotics 
also attributes to significant mortality (280).  
A significant proportion of the cases with a presumably viral disease in Paper I-II did not 
test positive for any virus. NGS screening of respiratory samples will likely result in the 
discovery of additional respiratory viruses in the future. Moreover, metagenomics studies 
assessing the complete microbiome will be critical to improve our understanding of interactions 
between respiratory microbes.  
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING  
Luftvägsinfektion, främst lunginflammation, är den enskilt vanligaste dödsorsaken hos barn i 
världen. Luftvägsinfektioner orsakas av både virus och bakterier. Sedan 1940-talet har 
upptäckten av antibiotika revolutionerat behandlingsmöjligheterna mot bakterieinfektioner. 
Tyvärr har det frikostiga användandet av antibiotika lett till att många bakterier idag är 
motståndskraftiga mot behandling och det är därför av största vikt att begränsa användandet av 
antibiotika till de fall där behandlingen är nödvändig för att kunna bromsa denna utveckling. 
Vad gäller behandling av virusinfektioner finns idag endast ett mycket begränsat antal antivirala 
läkemedel och vacciner riktade mot luftvägsvirus. Medan bakterieinfektioners roll är väl 
studerad, är många frågor fortfarande obesvarade avseende virusorsakade luftvägsinfektioner. 
Detta trots att majoriteten av alla luftvägsinfektioner orsakas av virus.  
Nya molekylärbaserade metoder har revolutionerat diagnostiken av virusinfektioner. Från att i 
hög grad ha klumpat ihop samtliga virusinfektioner under begreppet “viros” börjar vi nu sakta 
bilda oss en uppfattning om skillnader i sjukdomsbild och -förlopp för enskilda luftvägsvirus. 
Denna avhandling utgör en vidare kartläggning av detta med målet att bidra till en bättre 
förståelse för virusorsakade luftvägsinfektioner hos barn.  
När svininfluensapandemin nådde Sverige under hösten 2009, blev den mindre dramatisk och 
hade ett långsammare spridningsförlopp än förväntat. En bidragande orsak till detta föreslogs 
vara att influensavirusets spridning hämmades av en samtidig epidemi av rhinovirus. I 
delstudie I studerades luftvägsvirus hos barn med influensaliknande sjukdom som 
sjukhusvårdades på Astrid Lindgrens barnsjukhus under svininfluensaepidemin 2009/2010. Vi 
fann att barnen hade en rad olika påvisbara virus och kombinationen influensavirus och 
rhinovirus var inte helt ovanlig. Resultaten talade således emot ovan nämnda hypotes. Vi tittade 
även på om barn med svininfluensa och samtidigt ett eller flera ytterligare virus var sjukare än 
de som endast hade svininfluensa men kunde inte hitta någon signifikant skillnad mellan dessa 
grupper. Dock försvårades analyserna av det begränsade antalet barn med svininfluensa samt 
avsaknaden av en jämförande kontrollgrupp med friska barn. 
Realtids-PCR som utvecklades på 1990-talet är en mycket känslig metod för att påvisa virus på 
molekylärnivå. Relevansen av ett PCR-fynd har dock ifrågasatts då metoden även tycks påvisa 
fragment av viruspartiklar från tidigare infektioner och rapporter har visat att PCR-positivitet är 
vanligt hos friska barn. I delstudie II undersöktes olika luftvägsvirus roll vid akut 
luftvägssjukdom samt betydelsen av ett PCR-fynd i en fall-kontrollstudie. Prov från bakre 
näshålan togs på barn under 5 år med akut luftvägssjukdom (fall) på Sachsska barnsjukhuset 
samt på friska barn (kontroller) på barnavårdscentraler i Stockholm och analyserades med PCR 
för 16 olika virus. Vi fann att respiratoriskt syncytievirus, metapneumovirus och 
parainfluensavirus var starkt kopplade till luftvägssjukdom. Detektion av bocavirus och 
rhinovirus var så pass vanligt hos kontrollerna att ett orsakssamband med en pågående sjukdom 
inte säkert kunde fastställas. Vidare detekterades enterovirus och coronavirus lika ofta i båda 
studiegrupperna och vår studie kunde således inte påvisa någon koppling mellan dessa virus 
och luftvägssjukdom. Slutligen fann vi att infektion med flera olika virus, så kallad koinfektion, 
var vanligt samt kopplat till svårare sjukdom. 
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Lunginflammation är den näst vanligaste dödsorsaken hos barn under fem år. Sjukdomen har 
traditionellt sett tillskrivits bakteriell orsak, vilket framförallt grundar sig på flertalet studier från 
70- och 80-talen där bakterierna Streptococcus pneumoniae (pneumokocker) och Haemophilus 
influenzae identifierades som de vanligaste orsakerna. Bekämpning av fattigdom och svält samt 
vaccinationsprogram mot pneumokocker och H. influenzae typ B har bidragit till ett minskat 
antal fall av sjukdomen. I delstudie III studerades olika luftvägsvirus roll vid lunginflammation 
hos barn med ytterligare en fall-kontrollstudie. Under 2011-2014 provtogs 119 barn med 
lunginflammation (fall) på Astrid Lindgrens barnsjukhus Huddinge samt på Sachsska 
barnsjukhuset. För varje fall provtogs två friska barn (kontroller) på barnavårdscentraler i 
Stockholm. Med hjälp av särskilda statistiska metoder kunde skillnader mellan studiegrupperna 
beaktas vad gäller underliggande sjukdomar, ålder och till viss del socioekonomi. Studien visade 
att respiratoriskt syncytievirus, metapneumovirus och influensavirus var starkt associerade till 
lunginflammation och tillsammans påvisades dessa virus hos 60% av barnen. Detta trots att 
95% av barnen bedömts ha en bakteriell sjukdom och således hade fått behandling med 
antibiotika. Studien visade att virusorsakad lunginflammation är en underdiagnostiserad 
sjukdom och lyfte fram det relativt nyupptäckta viruset metapneumovirus som ett viktigt mål 
för framtida antivirala läkemedel och vacciner. 
Barn som genomgår cellgiftbehandling mot cancer drabbas inte sällan av neutropeni, en 
hämning av immunförsvaret som gör dem extra känsliga för svåra bakterieinfektioner. Vid 
feber och samtidig neutropeni, så kallad neutropen feber, sätts därför behandling med 
antibiotika in frikostigt. I många fall kan dock ingen förklaring till febern hittas. Eftersom 
virusorsakade luftvägsinfektioner är en vanlig orsak till feber hos friska barn är det troligt att 
detta även är en vanlig orsak till feber hos barn med nedsatt immunförsvar. I delstudie IV 
undersöktes förekomsten av luftvägsvirus hos barn med neutropen feber på barncancercentrum 
vid Astrid Lindgrens sjukhus. Vi fann att en majoritet av barnen hade ett eller flera påvisbara 
luftvägsvirus under episoderna av neutropen feber medan bakteriefynd var sällsynta. Vidare var 
luftvägssymtom vanligt. I uppföljningsproverna hos barnen som testat positivt för något 
luftvägsvirus var viruset inte längre påvisbart i majoriteten av fallen. Detta talar för ett 
orsakssamband mellan virusinfektion i luftvägarna och neutropen feber. 
 
Sammanfattningsvis har studierna bidragit till en bättre förståelse för enskilda luftvägsvirus roll 
vid svår luftvägssjukdom hos barn, visat att många förmodade bakteriella infektioner hos barn 
sannolikt orsakas av virus samt belyst för- och nackdelar med rådande rutindiagnostik för 
luftvägsinfektioner. Förhoppningen är att dessa resultat kommer bidra till en minskad 
antibiotikaanvändning och ge incitament till att utveckla nya diagnostiska test, antivirala 
läkemedel och vacciner mot luftvägsvirus. 
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